<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963401</url>
  </required_header>
  <id_info>
    <org_study_id>B7931030</org_study_id>
    <secondary_id>2018-004241-16</secondary_id>
    <nct_id>NCT03963401</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis</brief_title>
  <official_title>A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PF-06700841 TO EVALUATE THE EFFICACY AT 16 WEEKS AND TO EVALUATE THE SAFETY AND EFFICACY UP TO 1 YEAR IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to&#xD;
      evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Actual">January 15, 2021</completion_date>
  <primary_completion_date type="Actual">April 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>ACR 20 was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level). The participants receiving placebo in the initial period (Day 1 - Week 16) were combined into a single placebo group, while those who received PF-06700841 (10 mg QD) in the initial period were combined into a single PF-06700841 10 mg QD group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR20 Response at Week 16 in the Subgroup of Participants Who Were Tumor Necrosis Factor (TNF) α Inhibitor naïve</measure>
    <time_frame>Week 16</time_frame>
    <description>ACR 20 was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level). The participants receiving placebo in the initial period (Day 1 - Week 16) were combined into a single placebo group, while those who received PF-06700841 (10 mg QD) in the initial period were combined into a single PF-06700841 10 mg QD group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR20 Response at Weeks 2, 4, 8, 12, 20, 28, 36, 44 and 52</measure>
    <time_frame>Weeks 2, 4, 8, 12, 20, 28, 36, 44 and 52</time_frame>
    <description>The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR20) was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR50 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR50) was calculated as a ≥50% improvement in tender and swollen joint counts and ≥50% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR70 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR70) was calculated as a ≥70% improvement in tender and swollen joint counts and ≥70% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tender/Painful Joint Count at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The tender/painful joints were assessed by a blinded assessor to determine the number of joints that were considered tender/painful using the following scale: Present/Absent/Not Done/Not Applicable (used for artificial or missing joints). Artificial joints was not assessed. Injected joints was counted according to their pre-injection status for the remainder of the study. The assessment was based on 68 joints. The score range was 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Swollen Joint Count at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The swollen joints were assessed by a blinded assessor to determine the number of joints that were considered swollen using the following scale: Present/Absent/Not Done/Not Applicable (used for artificial or missing joints). Artificial joints was not assessed. Injected joints was counted according to their pre-injection status for the remainder of the study. The assessment was based on 66 joints. The score range was 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Arthritis Pain at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>Participants assessed the severity of their arthritis pain using a 100 millimeter (mm) visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, with a higher score indicating a higher degree of pain. A negative change from baseline represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Arthritis at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>Participants answered the following question, &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot;. The participant's response was recorded using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (very well) and 100 (very poorly). VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, and a negative change from baseline represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Arthritis at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The blinded assessor assessed the participant's overall arthritis appears at the time of each visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (very good) and 100 (very poor). VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, and a negative change from baseline represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index (DI) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The HAQ-DI assessed the degree of difficulty a participant experienced in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question in the questionnaire, the level of difficulty is scored from 0 to 3 with 0 representing &quot;no difficulty,&quot; 1 as &quot;some difficulty,&quot; 2 as &quot;much difficulty,&quot; and 3 as &quot;unable to do&quot;. Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range was 0 to 3, with a higher score indicating more difficulty in performing daily living activities. A negative change from baseline represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>C-reactive protein (hsCRP) is an acute phase reactant, which is indicative of inflammation and of its severity. Blood samples were obtained at Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52 for determination of hsCRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 indicates a 75% or greater reduction in PASI scores from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a PASI 90 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 indicates a 90% or greater reduction in PASI scores from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a PASI 100 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 100 indicates a 100% reduction in PASI scores from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Enthesitis Score (Using the Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The SPARCC Enthesitis Index examines tenderness at sixteen sites: medial epicondyle humerus, lateral epicondyle humerus, supraspinatus insertion into greater tuberosity of humerus, greater trochanter, quadriceps insertion into superior border of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle (considered 1 site for scoring purposes), Achilles tendon insertion into calcaneum and plantar fascia insertion into calcaneum. Each site is classified on a dichotomous basis as either tender (score=1) or not tender (score=0). The SPARCC Enthesitis Index scores range from 0-16, with higher scores indicating higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Enthesitis Score (Using the Leeds Enthesitis Index) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The Leeds Enthesitis Index (LEI) examines tenderness at six sites: lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Each site is assessed as either tender (score=1) or not tender (score=0). The LEI scores range from 0-6, with higher scores indicating higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Dactylitis Severity Score (DSS) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The number of digits in hands and feet with dactylitis was evaluated by a blinded assessor. In addition, dactylitis severity was scored based upon digit tenderness using a scale of 0-3, where 0 = no tenderness to 3 = extreme tenderness, in each digit of the hands and feet. The range of total dactylitis scores was 0-60, with higher scores indicating greater severity. A negative change from baseline represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Nail Psoriasis Severity Index (NAPSI) Score at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>A target finger nail was evaluated by the blinded assessor using the NAPSI scale. At the baseline visit, the worst case fingernail was chosen and the same nail was evaluated consistently through the entire study. Each quadrant of the target nail was graded for nail matrix psoriasis (including any of the following parameters: pitting, leukonychia, red spots in lunula, nail plate crumbling) and nail bed psoriasis (including any of the following parameters: onycholysis, splinter hemorrhages, oil drop (salmon patch) discoloration, nail bed hyperkeratosis). The target nail NAPSI scores range from 0 to 8, with higher scores indicating higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Patient's Global Joint and Skin Assessment-Visual Analog Scale (PGJS-VAS) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>Participant's perception of disease was assessed using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (excellent) and 100 (poor). The rating corresponded to the way in which the participant felt over the past week in terms of how they were affected by their: 1) psoriasis and arthritis (global, PGA); 2) arthritis only (PJA) and 3) psoriasis only (PSA). Rescaled VAS score was used. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). A negative change from baseline represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The FACIT-F Scale is a patient completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Short-Form-36 Health Survey (SF-36) Version 2, Acute at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The SF-36 version 2 (Acute version) is a 36-item generic health status measure. It measures 8 general health concepts or domains: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). These 8 domains can also be summarized as physical and mental component scores. The summary component scores, Physical Component Summary (PCS) and Mental Component Summary (MCS), are based on a normalized sum of the 8 scale scores PF, RP, BP, GH, VT, SF, RE, and MH. All domains and summary components are scored such that a higher score indicates a higher functioning or health level. The minimum and maximum scores of the PCS Score are 22 and 59 respectively. The minimum and maximum scores of the MCS Score are 11 and 62 respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Minimal Disease Activity (MDA) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>A psoriatic arthritis participant was defined as having MDA response when 5 of the 7 following criteria were met: 1) tender joint count ≤1; 2) swollen joint count ≤1; 3) Psoriasis Area and Severity Index (quantifying the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area affected) score ≤1 or Body Surface Area (assessment of body surface area involved in psoriasis) ≤3%; 4) Patient's Assessment of Arthritis Pain (assessment of the patient's level of pain using a horizontal 100 mm visual analog scale) ≤15 mm; 5) Patient's Global Arthritis Assessment (patient's overall assessment of how the arthritis was doing by a 100 mm visual analog scale) ≤20 mm; 6) Health Assessment Questionnaire - Disability Index (assessment of the degree of difficulty a patient experienced) score ≤0.5; 7) tender entheseal points (assessment of tenderness using Leed's Enthesitis Index) ≤1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Very Low Disease Activity (VLDA) Response at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>A participant was in VLDA when all the 7 following criteria were met: 1) tender joint count ≤1; 2) swollen joint count ≤1; 3) Psoriasis Area and Severity Index (quantifying the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area affected) score ≤1 or Body Surface Area (assessment of body surface area involved in psoriasis) ≤3%; 4) Patient's Assessment of Arthritis Pain (assessment of the patient's level of pain using a horizontal 100 mm visual analog scale) ≤15 mm; 5) Patient's Global Arthritis Assessment (patient's overall assessment of how the arthritis was doing by a 100 mm visual analog scale) ≤20 mm; 6) Health Assessment Questionnaire - Disability Index (assessment of the degree of difficulty a patient experienced) score ≤0.5; 7) tender entheseal points (assessment of tenderness using Leed's Enthesitis Index) ≤1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Disease Activity Index for Reactive Arthritis/PsA (DAREA/DAPSA) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>DAREA/DAPSA is a composite instrument to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count + swollen joint count (using SJC66/ TJC68 assessments), Patient's Global Assessment of Arthritis (PtGA in cm), Patient's Assessment of Arthritis Pain (PAIN in cm) and C-reactive protein (CRP) (in mg/dL). Since DAREA reflects domains found important in PsA, it has been proposed to serve as a Disease Activity Index for Psoriatic Arthritis (DAPSA). DAREA/DAPSA was calculated as follows: DAREA/DAPSA= SJC66 + TJC68 + PtGA + PAIN + CRP. A negative change from baseline represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving the Psoriatic Arthritis Response Criteria (PsARC) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>The PsARC response was defined as improvement in two of the following 4 criteria, one of which must be joint pain or swelling, without worsening in any measure: (1) ≥20% improvement in Physician's Global Assessment of Arthritis (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity); (2) ≥20% improvement in Patient's Global Assessment of Arthritis (the patient's overall assessment of how the arthritis was doing by a visual analog scale); (3) ≥30% improvement in tender joint count (68); and (4) ≥30% improvement in swollen joint count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</measure>
    <time_frame>Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
    <description>PASDAS is a composite psoriatic arthritis disease activity score that includes the following components: patient's global joint and skin assessment (visual analog scale in mm), physician's global psoriatic arthritis assessment (visual analog scale in mm), swollen (66 joints) and tender joint counts (68 joints), Leeds Enthesitis Index score, tender dactylitic digit score, physical component summary score (PCS) of Short Form 36 Health Survey and C-reactive protein (mg/L). Any missing component would result in PASDAS as missing. A higher PASDAS score indicates a higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (All Causalities)</measure>
    <time_frame>Baseline (Day 1) through Week 56</time_frame>
    <description>Treatment-emergent AEs are those with initial onset or that worsen in severity after the first dose of the study medication. All AEs in the table below were treatment-emergent AEs. An SAE is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the participant or may require intervention to prevent one of the other AE outcomes. Severe AEs were defined as AEs that interfered significantly with participant's usual function. Both SAEs and severe AEs were according to the investigator's assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (Treatment-related)</measure>
    <time_frame>Baseline (Day 1) through Week 56</time_frame>
    <description>Treatment-emergent AEs are those with initial onset or that worsen in severity after the first dose of the study medication. All AEs in the table below were treatment-emergent AEs. An SAE is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the participant or may require intervention to prevent one of the other AE outcomes. Severe AEs were defined as AEs that interfered significantly with participant's usual function. Both SAEs and severe AEs were according to the investigator's assessment. Treatment-related AEs were also determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued From Study Due to Treatment-emergent AEs From Baseline (Day 1) Through Week 56</measure>
    <time_frame>Baseline (Day 1) through Week 56</time_frame>
    <description>An AE is any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of the study medication.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>PF-06700841 60 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 60 mg once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 30 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 30 mg once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 10 mg once daily followed by 60 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 10 mg once daily for 16 weeks, followed by 60 mg once daily until Week 52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 10 mg once daily followed by 30 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 10 mg once daily for 16 weeks, followed by 30 mg once daily until Week 52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo once daily followed by 60 mg once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 16 weeks, followed by PF-06700841 60 mg once daily until Week 52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo once daily followed by 30 mg once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 16 weeks, followed by PF-06700841 30 mg once daily until Week 52</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06700841</intervention_name>
    <description>Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.</description>
    <arm_group_label>PF-06700841 10 mg once daily followed by 30 mg once daily</arm_group_label>
    <arm_group_label>PF-06700841 10 mg once daily followed by 60 mg once daily</arm_group_label>
    <arm_group_label>PF-06700841 30 mg once daily</arm_group_label>
    <arm_group_label>PF-06700841 60 mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.</description>
    <arm_group_label>Placebo once daily followed by 30 mg once daily</arm_group_label>
    <arm_group_label>Placebo once daily followed by 60 mg once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Active arthritis at screening/baseline as indicated by &gt;/= 3 tender/painful and 3&#xD;
             swollen joints.&#xD;
&#xD;
          -  Active plaque psoriasis at screening and baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-plaque forms of psoriasis (with exception of nail psoriasis).&#xD;
&#xD;
          -  History of autoimmune rheumatic disease other than PsA; also prior history of or&#xD;
             current, rheumatic inflammatory disease other than PsA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Research Unit</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Trimontium OOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Pulmed&quot;</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment ''Plovdiv'' AD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4027</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Pirogov&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Diagnostic-Consulting Center XVII - Sofia&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1505</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L.K.N. Arthrocentrum s.r.o.</name>
      <address>
        <city>Hlucin</city>
        <zip>748 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Czech a.s.</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Prague s.r.o.</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICAL PLUS s.r.o.</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>68601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innomedica OU</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical and Basic Research</name>
      <address>
        <city>Tallinn</city>
        <zip>10128</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>11312</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualiclinic Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITAL MEDICAL CENTER Orvosi es Fogorvosi Kozpont</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences, Kauno klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Osteoporosis Center</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-09310</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZDROWIE Osteo-Medic s.c. L. I A. Racewicz, A. i J. Supronik</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Daniluk Nowak Sp. Jawna</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zespol Poradni Specjalistycznych &quot;REUMED&quot; Filia nr 2</name>
      <address>
        <city>Lublin</city>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Lecznica Mak-Med s.c.</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia - Centrum Medyczne Nowa Sol</name>
      <address>
        <city>Nowa Sol</city>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ai Centrum Medyczne Sp. z o.o. Sp. k.</name>
      <address>
        <city>Poznan</city>
        <zip>61-113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatna Praktyka Lekarska Prof. UM dr hab. med. Pawel Hrycaj</name>
      <address>
        <city>Poznan</city>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCMed Oddzial Sochaczew</name>
      <address>
        <city>Sochaczew</city>
        <zip>96-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NASZ LEKARZ Przychodnie Medyczne</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>REUMATIKA - Centrum Reumatologii NZOZ</name>
      <address>
        <city>Warszawa</city>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Family Outpatient clinic #4&quot;</name>
      <address>
        <city>Korolev</city>
        <state>Moscow Region</state>
        <zip>141060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGBOU VO &quot;Orenburg State Medical University&quot; of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Orenburg</city>
        <zip>460000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ &quot;Orenburg Regional Clinical Hospital&quot;</name>
      <address>
        <city>Orenburg</city>
        <zip>460018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of the Republic of Karelia &quot;Republican Hospital n. a. V.A. Baranov&quot;</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185910</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBEI of HE &quot;Ryazan State Medical University n. a academician I.P.Pavlov&quot;</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBI of Ryazan Region &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Ryazan</city>
        <zip>390039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Sanavita&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC &quot;BioMed&quot;</name>
      <address>
        <city>Vladimir</city>
        <zip>600005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Autonomous Healthcare Institution of Yaroslavl Region</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Treatment and Rehabilitation Niska Banja</name>
      <address>
        <city>Niska Banja</city>
        <zip>18205</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodny ustav reumatickych chorob</name>
      <address>
        <city>Piestany</city>
        <zip>921 12</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. Zuzana Cizmarikova, s.r.o.</name>
      <address>
        <city>Poprad</city>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>REUMEX s.r.o.</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>979 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario A Coruna</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quironsalud Infanta Luisa</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Belarus</country>
  </removed_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7931030</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <reference>
    <citation>Banfield C, Scaramozza M, Zhang W, Kieras E, Page KM, Fensome A, Vincent M, Dowty ME, Goteti K, Winkle PJ, Peeva E. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis. J Clin Pharmacol. 2018 Apr;58(4):434-447. doi: 10.1002/jcph.1046. Epub 2017 Dec 21.</citation>
    <PMID>29266308</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <results_first_submitted>June 18, 2021</results_first_submitted>
  <results_first_submitted_qc>August 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 4, 2021</results_first_posted>
  <disposition_first_submitted>November 12, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 2, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 4, 2021</disposition_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spondyloarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>PF-06700841</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT03963401/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 2, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT03963401/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 219 participants were enrolled in this study and 1 of them didn't receive any study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
          <description>PF-06700841 tablet was administered orally at 60 milligram (mg) once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="P2">
          <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
          <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="P3">
          <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
          <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg QD during the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="P4">
          <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
          <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="P5">
          <title>Placebo -&gt; PF-06700841 60 mg QD</title>
          <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="P6">
          <title>Placebo -&gt; PF-06700841 30 mg QD</title>
          <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Period (Day 1 - Week 16)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="31"/>
                <participants group_id="P6" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Period (Week 17 - Week 52)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="31"/>
                <participants group_id="P6" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Longer Meets Eligibility Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis population included all participants who were randomized to the study and received at least one dose of the randomized study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
          <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="B2">
          <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
          <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="B3">
          <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
          <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg QD during the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="B4">
          <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
          <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="B5">
          <title>Placebo -&gt; PF-06700841 60 mg QD</title>
          <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="B6">
          <title>Placebo -&gt; PF-06700841 30 mg QD</title>
          <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="34"/>
            <count group_id="B6" value="33"/>
            <count group_id="B7" value="218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.7" spread="11.47"/>
                    <measurement group_id="B2" value="45.9" spread="10.23"/>
                    <measurement group_id="B3" value="47.8" spread="14.16"/>
                    <measurement group_id="B4" value="47.7" spread="12.95"/>
                    <measurement group_id="B5" value="47.9" spread="12.58"/>
                    <measurement group_id="B6" value="48.5" spread="11.84"/>
                    <measurement group_id="B7" value="47.6" spread="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0" lower_limit="24" upper_limit="70"/>
                    <measurement group_id="B2" value="46.0" lower_limit="26" upper_limit="73"/>
                    <measurement group_id="B3" value="43.5" lower_limit="22" upper_limit="71"/>
                    <measurement group_id="B4" value="47.0" lower_limit="28" upper_limit="73"/>
                    <measurement group_id="B5" value="48.0" lower_limit="21" upper_limit="69"/>
                    <measurement group_id="B6" value="50.0" lower_limit="23" upper_limit="72"/>
                    <measurement group_id="B7" value="48.0" lower_limit="21" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 16</title>
        <description>ACR 20 was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level). The participants receiving placebo in the initial period (Day 1 - Week 16) were combined into a single placebo group, while those who received PF-06700841 (10 mg QD) in the initial period were combined into a single PF-06700841 10 mg QD group.</description>
        <time_frame>Week 16</time_frame>
        <population>All participants who received at least 1 dose of the randomized study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 10 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during the initial period (from Day 1 to Week 16).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg QD during the initial period (from Day 1 to Week 16).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an American College of Rheumatology 20 (ACR20) Response at Week 16</title>
          <description>ACR 20 was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level). The participants receiving placebo in the initial period (Day 1 - Week 16) were combined into a single placebo group, while those who received PF-06700841 (10 mg QD) in the initial period were combined into a single PF-06700841 10 mg QD group.</description>
          <population>All participants who received at least 1 dose of the randomized study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.28" lower_limit="31.42" upper_limit="55.15"/>
                    <measurement group_id="O2" value="64.52" lower_limit="47.67" upper_limit="81.36"/>
                    <measurement group_id="O3" value="66.67" lower_limit="54.74" upper_limit="78.59"/>
                    <measurement group_id="O4" value="74.58" lower_limit="63.47" upper_limit="85.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1172</p_value>
            <method>Normal approximation, Dunnett's method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>21.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.51</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.94</ci_lower_limit>
            <ci_upper_limit>38.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0197</p_value>
            <method>Normal approximation, Dunnett's Method</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>23.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.58</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.26</ci_lower_limit>
            <ci_upper_limit>37.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Normal approximation, Dunnett's Method</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>31.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.29</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.65</ci_lower_limit>
            <ci_upper_limit>44.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR20 Response at Week 16 in the Subgroup of Participants Who Were Tumor Necrosis Factor (TNF) α Inhibitor naïve</title>
        <description>ACR 20 was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level). The participants receiving placebo in the initial period (Day 1 - Week 16) were combined into a single placebo group, while those who received PF-06700841 (10 mg QD) in the initial period were combined into a single PF-06700841 10 mg QD group.</description>
        <time_frame>Week 16</time_frame>
        <population>All participants who received at least 1 dose of the randomized study treatment with prior TNFα naïve.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 10 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during the initial period (from Day 1 to Week 16).</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg QD during the initial period (from Day 1 to Week 16).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR20 Response at Week 16 in the Subgroup of Participants Who Were Tumor Necrosis Factor (TNF) α Inhibitor naïve</title>
          <description>ACR 20 was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level). The participants receiving placebo in the initial period (Day 1 - Week 16) were combined into a single placebo group, while those who received PF-06700841 (10 mg QD) in the initial period were combined into a single PF-06700841 10 mg QD group.</description>
          <population>All participants who received at least 1 dose of the randomized study treatment with prior TNFα naïve.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.33" lower_limit="30.79" upper_limit="55.87"/>
                    <measurement group_id="O2" value="64.29" lower_limit="46.54" upper_limit="82.03"/>
                    <measurement group_id="O3" value="69.64" lower_limit="57.60" upper_limit="81.69"/>
                    <measurement group_id="O4" value="74.55" lower_limit="63.03" upper_limit="86.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0588</p_value>
            <method>Normal approximation method</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>20.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.09</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.72</ci_lower_limit>
            <ci_upper_limit>39.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>Normal approximation method</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>26.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.87</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.72</ci_lower_limit>
            <ci_upper_limit>40.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Normal approximation method</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>31.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.68</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.93</ci_lower_limit>
            <ci_upper_limit>45.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR20 Response at Weeks 2, 4, 8, 12, 20, 28, 36, 44 and 52</title>
        <description>The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR20) was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).</description>
        <time_frame>Weeks 2, 4, 8, 12, 20, 28, 36, 44 and 52</time_frame>
        <population>All participants who received at least 1 dose of the randomized study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR20 Response at Weeks 2, 4, 8, 12, 20, 28, 36, 44 and 52</title>
          <description>The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR20) was calculated as a ≥20% improvement in tender and swollen joint counts and ≥20% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).</description>
          <population>All participants who received at least 1 dose of the randomized study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.67" lower_limit="11.24" upper_limit="32.09"/>
                    <measurement group_id="O2" value="18.33" lower_limit="8.54" upper_limit="28.12"/>
                    <measurement group_id="O3" value="18.75" lower_limit="0.00" upper_limit="37.87"/>
                    <measurement group_id="O4" value="3.13" lower_limit="0.00" upper_limit="11.65"/>
                    <measurement group_id="O5" value="5.88" lower_limit="0.00" upper_limit="13.79"/>
                    <measurement group_id="O6" value="18.18" lower_limit="5.02" upper_limit="31.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.00" lower_limit="32.41" upper_limit="57.59"/>
                    <measurement group_id="O2" value="51.67" lower_limit="39.02" upper_limit="64.31"/>
                    <measurement group_id="O3" value="31.25" lower_limit="8.54" upper_limit="53.96"/>
                    <measurement group_id="O4" value="20.00" lower_limit="0.00" upper_limit="40.24"/>
                    <measurement group_id="O5" value="14.71" lower_limit="2.80" upper_limit="26.61"/>
                    <measurement group_id="O6" value="24.24" lower_limit="9.62" upper_limit="38.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" lower_limit="54.74" upper_limit="78.59"/>
                    <measurement group_id="O2" value="55.00" lower_limit="42.41" upper_limit="67.59"/>
                    <measurement group_id="O3" value="50.00" lower_limit="25.50" upper_limit="74.50"/>
                    <measurement group_id="O4" value="40.00" lower_limit="15.21" upper_limit="64.79"/>
                    <measurement group_id="O5" value="35.29" lower_limit="19.23" upper_limit="51.36"/>
                    <measurement group_id="O6" value="42.42" lower_limit="25.56" upper_limit="59.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.00" lower_limit="58.40" upper_limit="81.60"/>
                    <measurement group_id="O2" value="63.33" lower_limit="51.14" upper_limit="75.53"/>
                    <measurement group_id="O3" value="56.25" lower_limit="31.94" upper_limit="80.56"/>
                    <measurement group_id="O4" value="60.00" lower_limit="35.21" upper_limit="84.79"/>
                    <measurement group_id="O5" value="44.12" lower_limit="27.43" upper_limit="60.81"/>
                    <measurement group_id="O6" value="39.39" lower_limit="22.72" upper_limit="56.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.67" lower_limit="71.88" upper_limit="91.46"/>
                    <measurement group_id="O2" value="80.00" lower_limit="69.88" upper_limit="90.12"/>
                    <measurement group_id="O3" value="68.75" lower_limit="46.04" upper_limit="91.46"/>
                    <measurement group_id="O4" value="60.00" lower_limit="35.21" upper_limit="84.79"/>
                    <measurement group_id="O5" value="73.53" lower_limit="58.70" upper_limit="88.36"/>
                    <measurement group_id="O6" value="75.76" lower_limit="61.14" upper_limit="90.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.33" lower_limit="62.14" upper_limit="84.52"/>
                    <measurement group_id="O2" value="78.33" lower_limit="67.91" upper_limit="88.76"/>
                    <measurement group_id="O3" value="68.75" lower_limit="46.04" upper_limit="91.46"/>
                    <measurement group_id="O4" value="73.33" lower_limit="50.95" upper_limit="95.71"/>
                    <measurement group_id="O5" value="64.71" lower_limit="48.64" upper_limit="80.77"/>
                    <measurement group_id="O6" value="81.82" lower_limit="68.66" upper_limit="94.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" lower_limit="54.74" upper_limit="78.59"/>
                    <measurement group_id="O2" value="78.33" lower_limit="67.91" upper_limit="88.76"/>
                    <measurement group_id="O3" value="68.75" lower_limit="46.04" upper_limit="91.46"/>
                    <measurement group_id="O4" value="80.00" lower_limit="59.76" upper_limit="100.00"/>
                    <measurement group_id="O5" value="64.71" lower_limit="48.64" upper_limit="80.77"/>
                    <measurement group_id="O6" value="81.82" lower_limit="68.66" upper_limit="94.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.33" lower_limit="56.56" upper_limit="80.10"/>
                    <measurement group_id="O2" value="73.33" lower_limit="62.14" upper_limit="84.52"/>
                    <measurement group_id="O3" value="62.50" lower_limit="38.78" upper_limit="86.22"/>
                    <measurement group_id="O4" value="73.33" lower_limit="50.95" upper_limit="95.71"/>
                    <measurement group_id="O5" value="67.65" lower_limit="51.92" upper_limit="83.37"/>
                    <measurement group_id="O6" value="75.76" lower_limit="61.14" upper_limit="90.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.67" lower_limit="49.36" upper_limit="73.97"/>
                    <measurement group_id="O2" value="70.00" lower_limit="58.40" upper_limit="81.60"/>
                    <measurement group_id="O3" value="56.25" lower_limit="31.94" upper_limit="80.56"/>
                    <measurement group_id="O4" value="60.00" lower_limit="35.21" upper_limit="84.79"/>
                    <measurement group_id="O5" value="61.76" lower_limit="45.43" upper_limit="78.10"/>
                    <measurement group_id="O6" value="66.67" lower_limit="50.58" upper_limit="82.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR50 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR50) was calculated as a ≥50% improvement in tender and swollen joint counts and ≥50% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>All participants who received at least 1 dose of the randomized study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR50 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR50) was calculated as a ≥50% improvement in tender and swollen joint counts and ≥50% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).</description>
          <population>All participants who received at least 1 dose of the randomized study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" lower_limit="0.35" upper_limit="12.98"/>
                    <measurement group_id="O2" value="1.67" lower_limit="0.00" upper_limit="4.91"/>
                    <measurement group_id="O3" value="2.94" lower_limit="0.00" upper_limit="10.97"/>
                    <measurement group_id="O4" value="3.13" lower_limit="0.00" upper_limit="11.65"/>
                    <measurement group_id="O5" value="1.43" lower_limit="0.00" upper_limit="5.36"/>
                    <measurement group_id="O6" value="1.47" lower_limit="0.00" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33" lower_limit="4.73" upper_limit="21.93"/>
                    <measurement group_id="O2" value="16.67" lower_limit="7.24" upper_limit="26.10"/>
                    <measurement group_id="O3" value="2.94" lower_limit="0.00" upper_limit="10.97"/>
                    <measurement group_id="O4" value="6.67" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O5" value="2.94" lower_limit="0.00" upper_limit="8.62"/>
                    <measurement group_id="O6" value="6.06" lower_limit="0.00" upper_limit="14.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.67" lower_limit="19.90" upper_limit="43.44"/>
                    <measurement group_id="O2" value="25.00" lower_limit="14.04" upper_limit="35.96"/>
                    <measurement group_id="O3" value="18.75" lower_limit="0.00" upper_limit="37.87"/>
                    <measurement group_id="O4" value="13.33" lower_limit="0.00" upper_limit="30.54"/>
                    <measurement group_id="O5" value="11.76" lower_limit="0.93" upper_limit="22.59"/>
                    <measurement group_id="O6" value="15.15" lower_limit="2.92" upper_limit="27.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.33" lower_limit="30.79" upper_limit="55.87"/>
                    <measurement group_id="O2" value="31.67" lower_limit="19.90" upper_limit="43.44"/>
                    <measurement group_id="O3" value="31.25" lower_limit="8.54" upper_limit="53.96"/>
                    <measurement group_id="O4" value="20.00" lower_limit="0.00" upper_limit="40.24"/>
                    <measurement group_id="O5" value="23.53" lower_limit="9.27" upper_limit="37.79"/>
                    <measurement group_id="O6" value="12.12" lower_limit="0.99" upper_limit="23.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.07" lower_limit="31.40" upper_limit="56.74"/>
                    <measurement group_id="O2" value="48.33" lower_limit="35.69" upper_limit="60.98"/>
                    <measurement group_id="O3" value="31.25" lower_limit="8.54" upper_limit="53.96"/>
                    <measurement group_id="O4" value="33.33" lower_limit="9.48" upper_limit="57.19"/>
                    <measurement group_id="O5" value="14.71" lower_limit="2.80" upper_limit="26.61"/>
                    <measurement group_id="O6" value="6.06" lower_limit="0.00" upper_limit="14.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.67" lower_limit="49.36" upper_limit="73.97"/>
                    <measurement group_id="O2" value="53.33" lower_limit="40.71" upper_limit="65.96"/>
                    <measurement group_id="O3" value="37.50" lower_limit="13.78" upper_limit="61.22"/>
                    <measurement group_id="O4" value="40.00" lower_limit="15.21" upper_limit="64.79"/>
                    <measurement group_id="O5" value="44.12" lower_limit="27.43" upper_limit="60.81"/>
                    <measurement group_id="O6" value="45.45" lower_limit="28.47" upper_limit="62.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.67" lower_limit="44.13" upper_limit="69.21"/>
                    <measurement group_id="O2" value="51.67" lower_limit="39.02" upper_limit="64.31"/>
                    <measurement group_id="O3" value="43.75" lower_limit="19.44" upper_limit="68.06"/>
                    <measurement group_id="O4" value="53.33" lower_limit="28.09" upper_limit="78.58"/>
                    <measurement group_id="O5" value="41.18" lower_limit="24.63" upper_limit="57.72"/>
                    <measurement group_id="O6" value="66.67" lower_limit="50.58" upper_limit="82.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.33" lower_limit="40.71" upper_limit="65.96"/>
                    <measurement group_id="O2" value="56.67" lower_limit="44.13" upper_limit="69.21"/>
                    <measurement group_id="O3" value="50.00" lower_limit="25.50" upper_limit="74.50"/>
                    <measurement group_id="O4" value="66.67" lower_limit="42.81" upper_limit="90.52"/>
                    <measurement group_id="O5" value="50.00" lower_limit="33.19" upper_limit="66.81"/>
                    <measurement group_id="O6" value="57.58" lower_limit="40.71" upper_limit="74.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.67" lower_limit="44.13" upper_limit="69.21"/>
                    <measurement group_id="O2" value="55.00" lower_limit="42.41" upper_limit="67.59"/>
                    <measurement group_id="O3" value="43.75" lower_limit="19.44" upper_limit="68.06"/>
                    <measurement group_id="O4" value="60.00" lower_limit="35.21" upper_limit="84.79"/>
                    <measurement group_id="O5" value="58.82" lower_limit="42.28" upper_limit="75.37"/>
                    <measurement group_id="O6" value="63.64" lower_limit="47.22" upper_limit="80.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.67" lower_limit="34.04" upper_limit="59.29"/>
                    <measurement group_id="O2" value="58.33" lower_limit="45.86" upper_limit="70.81"/>
                    <measurement group_id="O3" value="43.75" lower_limit="19.44" upper_limit="68.06"/>
                    <measurement group_id="O4" value="46.67" lower_limit="21.42" upper_limit="71.91"/>
                    <measurement group_id="O5" value="41.18" lower_limit="24.63" upper_limit="57.72"/>
                    <measurement group_id="O6" value="51.52" lower_limit="34.46" upper_limit="68.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR70 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR70) was calculated as a ≥70% improvement in tender and swollen joint counts and ≥70% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>All participants who received at least 1 dose of the randomized study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR70 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR70) was calculated as a ≥70% improvement in tender and swollen joint counts and ≥70% improvement in 3 of the 5 remaining ACR core set measures: patient pain assessment (a horizontal visual analog scale assessment of the patient's level of pain), patient global assessment (the patient's overall assessment of how the arthritis was doing by a visual analog scale), physician global assessment (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity), patient self-assessed disability (a validated and reliable patient self-assessment instrument which measured physical functions in rheumatoid arthritis patients) and an acute-phase reactant (C-reactive protein level).</description>
          <population>All participants who received at least 1 dose of the randomized study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="0.00" upper_limit="7.88"/>
                    <measurement group_id="O2" value="1.67" lower_limit="0.00" upper_limit="4.91"/>
                    <measurement group_id="O3" value="2.94" lower_limit="0.00" upper_limit="10.97"/>
                    <measurement group_id="O4" value="3.13" lower_limit="0.00" upper_limit="11.65"/>
                    <measurement group_id="O5" value="1.43" lower_limit="0.00" upper_limit="5.36"/>
                    <measurement group_id="O6" value="1.47" lower_limit="0.00" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="0.00" upper_limit="10.51"/>
                    <measurement group_id="O2" value="5.00" lower_limit="0.00" upper_limit="10.51"/>
                    <measurement group_id="O3" value="2.94" lower_limit="0.00" upper_limit="10.97"/>
                    <measurement group_id="O4" value="3.13" lower_limit="0.00" upper_limit="11.65"/>
                    <measurement group_id="O5" value="1.43" lower_limit="0.00" upper_limit="5.36"/>
                    <measurement group_id="O6" value="1.47" lower_limit="0.00" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.67" lower_limit="3.54" upper_limit="19.79"/>
                    <measurement group_id="O2" value="11.67" lower_limit="3.54" upper_limit="19.79"/>
                    <measurement group_id="O3" value="6.25" lower_limit="0.00" upper_limit="18.11"/>
                    <measurement group_id="O4" value="3.13" lower_limit="0.00" upper_limit="11.65"/>
                    <measurement group_id="O5" value="2.94" lower_limit="0.00" upper_limit="8.62"/>
                    <measurement group_id="O6" value="3.03" lower_limit="0.00" upper_limit="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.67" lower_limit="11.24" upper_limit="32.09"/>
                    <measurement group_id="O2" value="18.33" lower_limit="8.54" upper_limit="28.12"/>
                    <measurement group_id="O3" value="6.25" lower_limit="0.00" upper_limit="18.11"/>
                    <measurement group_id="O4" value="6.67" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O5" value="1.43" lower_limit="0.00" upper_limit="5.36"/>
                    <measurement group_id="O6" value="9.09" lower_limit="0.00" upper_limit="18.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.73" lower_limit="12.87" upper_limit="34.58"/>
                    <measurement group_id="O2" value="26.67" lower_limit="15.48" upper_limit="37.86"/>
                    <measurement group_id="O3" value="6.25" lower_limit="0.00" upper_limit="18.11"/>
                    <measurement group_id="O4" value="13.33" lower_limit="0.00" upper_limit="30.54"/>
                    <measurement group_id="O5" value="1.43" lower_limit="0.00" upper_limit="5.36"/>
                    <measurement group_id="O6" value="1.47" lower_limit="0.00" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.00" lower_limit="22.93" upper_limit="47.07"/>
                    <measurement group_id="O2" value="30.00" lower_limit="18.40" upper_limit="41.60"/>
                    <measurement group_id="O3" value="12.50" lower_limit="0.00" upper_limit="28.70"/>
                    <measurement group_id="O4" value="20.00" lower_limit="0.00" upper_limit="40.24"/>
                    <measurement group_id="O5" value="23.53" lower_limit="9.27" upper_limit="37.79"/>
                    <measurement group_id="O6" value="27.27" lower_limit="12.08" upper_limit="42.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.67" lower_limit="24.47" upper_limit="48.86"/>
                    <measurement group_id="O2" value="38.33" lower_limit="26.03" upper_limit="50.64"/>
                    <measurement group_id="O3" value="18.75" lower_limit="0.00" upper_limit="37.87"/>
                    <measurement group_id="O4" value="26.67" lower_limit="4.29" upper_limit="49.05"/>
                    <measurement group_id="O5" value="23.53" lower_limit="9.27" upper_limit="37.79"/>
                    <measurement group_id="O6" value="42.42" lower_limit="25.56" upper_limit="59.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.00" lower_limit="27.60" upper_limit="52.40"/>
                    <measurement group_id="O2" value="35.00" lower_limit="22.93" upper_limit="47.07"/>
                    <measurement group_id="O3" value="37.50" lower_limit="13.78" upper_limit="61.22"/>
                    <measurement group_id="O4" value="26.67" lower_limit="4.29" upper_limit="49.05"/>
                    <measurement group_id="O5" value="35.29" lower_limit="19.23" upper_limit="51.36"/>
                    <measurement group_id="O6" value="39.39" lower_limit="22.72" upper_limit="56.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.67" lower_limit="34.04" upper_limit="59.29"/>
                    <measurement group_id="O2" value="45.00" lower_limit="32.41" upper_limit="57.59"/>
                    <measurement group_id="O3" value="37.50" lower_limit="13.78" upper_limit="61.22"/>
                    <measurement group_id="O4" value="40.00" lower_limit="15.21" upper_limit="64.79"/>
                    <measurement group_id="O5" value="23.53" lower_limit="9.27" upper_limit="37.79"/>
                    <measurement group_id="O6" value="51.52" lower_limit="34.46" upper_limit="68.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.33" lower_limit="26.03" upper_limit="50.64"/>
                    <measurement group_id="O2" value="45.00" lower_limit="32.41" upper_limit="57.59"/>
                    <measurement group_id="O3" value="31.25" lower_limit="8.54" upper_limit="53.96"/>
                    <measurement group_id="O4" value="26.67" lower_limit="4.29" upper_limit="49.05"/>
                    <measurement group_id="O5" value="35.29" lower_limit="19.23" upper_limit="51.36"/>
                    <measurement group_id="O6" value="42.42" lower_limit="25.56" upper_limit="59.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tender/Painful Joint Count at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The tender/painful joints were assessed by a blinded assessor to determine the number of joints that were considered tender/painful using the following scale: Present/Absent/Not Done/Not Applicable (used for artificial or missing joints). Artificial joints was not assessed. Injected joints was counted according to their pre-injection status for the remainder of the study. The assessment was based on 68 joints. The score range was 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline represents improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender/Painful Joint Count at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The tender/painful joints were assessed by a blinded assessor to determine the number of joints that were considered tender/painful using the following scale: Present/Absent/Not Done/Not Applicable (used for artificial or missing joints). Artificial joints was not assessed. Injected joints was counted according to their pre-injection status for the remainder of the study. The assessment was based on 68 joints. The score range was 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline represents improvement.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.33" spread="5.23"/>
                    <measurement group_id="O2" value="-2.7" spread="4.49"/>
                    <measurement group_id="O3" value="-4.7" spread="6.37"/>
                    <measurement group_id="O4" value="0.0" spread="2.70"/>
                    <measurement group_id="O5" value="-1.9" spread="3.27"/>
                    <measurement group_id="O6" value="-2.1" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="7.96"/>
                    <measurement group_id="O2" value="-5.1" spread="5.43"/>
                    <measurement group_id="O3" value="-5.6" spread="8.93"/>
                    <measurement group_id="O4" value="-2.8" spread="4.49"/>
                    <measurement group_id="O5" value="-3.4" spread="5.47"/>
                    <measurement group_id="O6" value="-4.3" spread="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="7.69"/>
                    <measurement group_id="O2" value="-6.8" spread="6.49"/>
                    <measurement group_id="O3" value="-7.9" spread="7.89"/>
                    <measurement group_id="O4" value="-4.4" spread="6.42"/>
                    <measurement group_id="O5" value="-5.0" spread="6.46"/>
                    <measurement group_id="O6" value="-4.6" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="8.19"/>
                    <measurement group_id="O2" value="-8.7" spread="7.27"/>
                    <measurement group_id="O3" value="-11.3" spread="7.32"/>
                    <measurement group_id="O4" value="-6.2" spread="8.43"/>
                    <measurement group_id="O5" value="-6.5" spread="6.69"/>
                    <measurement group_id="O6" value="-6.4" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" spread="8.01"/>
                    <measurement group_id="O2" value="-10.1" spread="7.33"/>
                    <measurement group_id="O3" value="-12.0" spread="8.80"/>
                    <measurement group_id="O4" value="-10.4" spread="8.69"/>
                    <measurement group_id="O5" value="-6.5" spread="5.78"/>
                    <measurement group_id="O6" value="-6.5" spread="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="8.20"/>
                    <measurement group_id="O2" value="-10.2" spread="6.60"/>
                    <measurement group_id="O3" value="-13.6" spread="9.65"/>
                    <measurement group_id="O4" value="-11.2" spread="10.95"/>
                    <measurement group_id="O5" value="-8.8" spread="5.94"/>
                    <measurement group_id="O6" value="-10.2" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" spread="8.38"/>
                    <measurement group_id="O2" value="-10.4" spread="7.04"/>
                    <measurement group_id="O3" value="-14.9" spread="9.99"/>
                    <measurement group_id="O4" value="-13.5" spread="12.21"/>
                    <measurement group_id="O5" value="-9.6" spread="6.39"/>
                    <measurement group_id="O6" value="-11.4" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="8.66"/>
                    <measurement group_id="O2" value="-10.7" spread="7.00"/>
                    <measurement group_id="O3" value="-16.2" spread="9.45"/>
                    <measurement group_id="O4" value="-13.8" spread="11.89"/>
                    <measurement group_id="O5" value="-10.4" spread="6.12"/>
                    <measurement group_id="O6" value="-11.4" spread="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.6" spread="8.54"/>
                    <measurement group_id="O2" value="-11.6" spread="7.91"/>
                    <measurement group_id="O3" value="-17.9" spread="10.07"/>
                    <measurement group_id="O4" value="-12.6" spread="13.23"/>
                    <measurement group_id="O5" value="-11.3" spread="6.47"/>
                    <measurement group_id="O6" value="-12.5" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.6" spread="9.11"/>
                    <measurement group_id="O2" value="-11.9" spread="7.69"/>
                    <measurement group_id="O3" value="-18.9" spread="10.74"/>
                    <measurement group_id="O4" value="-13.0" spread="12.25"/>
                    <measurement group_id="O5" value="-10.8" spread="5.53"/>
                    <measurement group_id="O6" value="-12.2" spread="9.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Swollen Joint Count at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The swollen joints were assessed by a blinded assessor to determine the number of joints that were considered swollen using the following scale: Present/Absent/Not Done/Not Applicable (used for artificial or missing joints). Artificial joints was not assessed. Injected joints was counted according to their pre-injection status for the remainder of the study. The assessment was based on 66 joints. The score range was 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline represents improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Swollen Joint Count at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The swollen joints were assessed by a blinded assessor to determine the number of joints that were considered swollen using the following scale: Present/Absent/Not Done/Not Applicable (used for artificial or missing joints). Artificial joints was not assessed. Injected joints was counted according to their pre-injection status for the remainder of the study. The assessment was based on 66 joints. The score range was 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline represents improvement.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="3.48"/>
                    <measurement group_id="O2" value="-2.7" spread="3.73"/>
                    <measurement group_id="O3" value="-4.6" spread="5.46"/>
                    <measurement group_id="O4" value="-2.1" spread="3.31"/>
                    <measurement group_id="O5" value="-2.0" spread="3.82"/>
                    <measurement group_id="O6" value="-2.0" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="4.42"/>
                    <measurement group_id="O2" value="-4.3" spread="3.64"/>
                    <measurement group_id="O3" value="-5.5" spread="5.51"/>
                    <measurement group_id="O4" value="-5.2" spread="8.14"/>
                    <measurement group_id="O5" value="-2.5" spread="3.11"/>
                    <measurement group_id="O6" value="-3.6" spread="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="5.42"/>
                    <measurement group_id="O2" value="-5.9" spread="4.50"/>
                    <measurement group_id="O3" value="-7.9" spread="4.72"/>
                    <measurement group_id="O4" value="-7.5" spread="7.54"/>
                    <measurement group_id="O5" value="-4.4" spread="5.42"/>
                    <measurement group_id="O6" value="-4.4" spread="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="5.89"/>
                    <measurement group_id="O2" value="-6.7" spread="4.69"/>
                    <measurement group_id="O3" value="-8.7" spread="6.97"/>
                    <measurement group_id="O4" value="-8.7" spread="8.04"/>
                    <measurement group_id="O5" value="-5.4" spread="5.26"/>
                    <measurement group_id="O6" value="-4.7" spread="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="5.53"/>
                    <measurement group_id="O2" value="-7.6" spread="5.10"/>
                    <measurement group_id="O3" value="-8.9" spread="7.94"/>
                    <measurement group_id="O4" value="-9.9" spread="8.98"/>
                    <measurement group_id="O5" value="-6.7" spread="5.80"/>
                    <measurement group_id="O6" value="-5.5" spread="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="5.31"/>
                    <measurement group_id="O2" value="-8.3" spread="5.12"/>
                    <measurement group_id="O3" value="-10.5" spread="8.42"/>
                    <measurement group_id="O4" value="-10.8" spread="9.10"/>
                    <measurement group_id="O5" value="-8.0" spread="6.29"/>
                    <measurement group_id="O6" value="-7.6" spread="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="4.34"/>
                    <measurement group_id="O2" value="-7.7" spread="5.27"/>
                    <measurement group_id="O3" value="-10.0" spread="7.66"/>
                    <measurement group_id="O4" value="-10.9" spread="9.00"/>
                    <measurement group_id="O5" value="-7.2" spread="5.79"/>
                    <measurement group_id="O6" value="-8.5" spread="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="4.35"/>
                    <measurement group_id="O2" value="-8.1" spread="4.97"/>
                    <measurement group_id="O3" value="-10.5" spread="7.55"/>
                    <measurement group_id="O4" value="-11.1" spread="9.30"/>
                    <measurement group_id="O5" value="-8.4" spread="5.60"/>
                    <measurement group_id="O6" value="-8.9" spread="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="4.87"/>
                    <measurement group_id="O2" value="-8.2" spread="5.05"/>
                    <measurement group_id="O3" value="-10.5" spread="6.84"/>
                    <measurement group_id="O4" value="-10.8" spread="9.93"/>
                    <measurement group_id="O5" value="-8.3" spread="5.57"/>
                    <measurement group_id="O6" value="-9.5" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="4.84"/>
                    <measurement group_id="O2" value="-8.1" spread="4.84"/>
                    <measurement group_id="O3" value="-11.1" spread="7.68"/>
                    <measurement group_id="O4" value="-10.7" spread="9.55"/>
                    <measurement group_id="O5" value="-8.5" spread="5.76"/>
                    <measurement group_id="O6" value="-9.2" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Assessment of Arthritis Pain at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>Participants assessed the severity of their arthritis pain using a 100 millimeter (mm) visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, with a higher score indicating a higher degree of pain. A negative change from baseline represents improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Assessment of Arthritis Pain at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>Participants assessed the severity of their arthritis pain using a 100 millimeter (mm) visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, with a higher score indicating a higher degree of pain. A negative change from baseline represents improvement.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="19.13"/>
                    <measurement group_id="O2" value="-8.0" spread="17.96"/>
                    <measurement group_id="O3" value="-5.3" spread="12.87"/>
                    <measurement group_id="O4" value="1.7" spread="21.20"/>
                    <measurement group_id="O5" value="-2.3" spread="11.89"/>
                    <measurement group_id="O6" value="-9.0" spread="17.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.4" spread="23.39"/>
                    <measurement group_id="O2" value="-18.5" spread="20.32"/>
                    <measurement group_id="O3" value="-12.4" spread="22.60"/>
                    <measurement group_id="O4" value="-7.9" spread="22.69"/>
                    <measurement group_id="O5" value="-10.1" spread="18.67"/>
                    <measurement group_id="O6" value="-9.6" spread="18.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.6" spread="23.55"/>
                    <measurement group_id="O2" value="-21.0" spread="22.46"/>
                    <measurement group_id="O3" value="-14.3" spread="27.34"/>
                    <measurement group_id="O4" value="-10.7" spread="25.94"/>
                    <measurement group_id="O5" value="-16.9" spread="22.67"/>
                    <measurement group_id="O6" value="-13.1" spread="22.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="25.72"/>
                    <measurement group_id="O2" value="-22.8" spread="22.19"/>
                    <measurement group_id="O3" value="-21.8" spread="24.25"/>
                    <measurement group_id="O4" value="-14.9" spread="24.90"/>
                    <measurement group_id="O5" value="-14.2" spread="24.54"/>
                    <measurement group_id="O6" value="-12.3" spread="24.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.4" spread="24.13"/>
                    <measurement group_id="O2" value="-25.0" spread="22.58"/>
                    <measurement group_id="O3" value="-26.5" spread="23.41"/>
                    <measurement group_id="O4" value="-30.2" spread="20.55"/>
                    <measurement group_id="O5" value="-13.7" spread="22.14"/>
                    <measurement group_id="O6" value="-14.6" spread="20.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.5" spread="24.12"/>
                    <measurement group_id="O2" value="-30.9" spread="22.91"/>
                    <measurement group_id="O3" value="-29.3" spread="24.07"/>
                    <measurement group_id="O4" value="-25.5" spread="29.91"/>
                    <measurement group_id="O5" value="-32.1" spread="22.84"/>
                    <measurement group_id="O6" value="-27.7" spread="26.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.7" spread="22.88"/>
                    <measurement group_id="O2" value="-32.2" spread="25.21"/>
                    <measurement group_id="O3" value="-34.6" spread="21.85"/>
                    <measurement group_id="O4" value="-35.2" spread="24.79"/>
                    <measurement group_id="O5" value="-29.6" spread="27.49"/>
                    <measurement group_id="O6" value="-37.4" spread="25.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.6" spread="25.14"/>
                    <measurement group_id="O2" value="-31.3" spread="26.58"/>
                    <measurement group_id="O3" value="-37.0" spread="29.87"/>
                    <measurement group_id="O4" value="-33.5" spread="36.99"/>
                    <measurement group_id="O5" value="-32.4" spread="21.11"/>
                    <measurement group_id="O6" value="-38.5" spread="26.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.8" spread="26.90"/>
                    <measurement group_id="O2" value="-36.5" spread="26.87"/>
                    <measurement group_id="O3" value="-41.6" spread="16.12"/>
                    <measurement group_id="O4" value="-34.1" spread="39.69"/>
                    <measurement group_id="O5" value="-35.0" spread="23.36"/>
                    <measurement group_id="O6" value="-40.0" spread="26.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.4" spread="26.39"/>
                    <measurement group_id="O2" value="-35.5" spread="27.76"/>
                    <measurement group_id="O3" value="-39.6" spread="21.95"/>
                    <measurement group_id="O4" value="-34.9" spread="31.79"/>
                    <measurement group_id="O5" value="-38.3" spread="22.84"/>
                    <measurement group_id="O6" value="-38.5" spread="25.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment of Arthritis at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>Participants answered the following question, &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot;. The participant's response was recorded using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (very well) and 100 (very poorly). VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, and a negative change from baseline represents improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment of Arthritis at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>Participants answered the following question, &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot;. The participant's response was recorded using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (very well) and 100 (very poorly). VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, and a negative change from baseline represents improvement.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="21.52"/>
                    <measurement group_id="O2" value="-10.9" spread="17.85"/>
                    <measurement group_id="O3" value="-5.4" spread="17.59"/>
                    <measurement group_id="O4" value="2.6" spread="19.66"/>
                    <measurement group_id="O5" value="-0.1" spread="17.33"/>
                    <measurement group_id="O6" value="-7.8" spread="17.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" spread="25.55"/>
                    <measurement group_id="O2" value="-20.5" spread="20.60"/>
                    <measurement group_id="O3" value="-12.3" spread="18.09"/>
                    <measurement group_id="O4" value="-8.9" spread="16.46"/>
                    <measurement group_id="O5" value="-2.0" spread="20.76"/>
                    <measurement group_id="O6" value="-3.3" spread="17.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.4" spread="24.61"/>
                    <measurement group_id="O2" value="-21.9" spread="24.29"/>
                    <measurement group_id="O3" value="-14.0" spread="21.37"/>
                    <measurement group_id="O4" value="-12.7" spread="19.88"/>
                    <measurement group_id="O5" value="-11.0" spread="26.22"/>
                    <measurement group_id="O6" value="-7.0" spread="22.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.8" spread="26.15"/>
                    <measurement group_id="O2" value="-26.2" spread="21.18"/>
                    <measurement group_id="O3" value="-20.0" spread="24.36"/>
                    <measurement group_id="O4" value="-12.4" spread="21.29"/>
                    <measurement group_id="O5" value="-12.2" spread="26.00"/>
                    <measurement group_id="O6" value="-8.0" spread="25.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.8" spread="22.31"/>
                    <measurement group_id="O2" value="-27.3" spread="21.62"/>
                    <measurement group_id="O3" value="-26.1" spread="25.26"/>
                    <measurement group_id="O4" value="-26.7" spread="19.05"/>
                    <measurement group_id="O5" value="-9.3" spread="23.48"/>
                    <measurement group_id="O6" value="-9.4" spread="21.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.8" spread="23.84"/>
                    <measurement group_id="O2" value="-31.4" spread="21.81"/>
                    <measurement group_id="O3" value="-27.6" spread="23.49"/>
                    <measurement group_id="O4" value="-22.8" spread="31.26"/>
                    <measurement group_id="O5" value="-28.8" spread="25.44"/>
                    <measurement group_id="O6" value="-25.5" spread="24.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.4" spread="20.78"/>
                    <measurement group_id="O2" value="-34.0" spread="23.87"/>
                    <measurement group_id="O3" value="-33.9" spread="22.09"/>
                    <measurement group_id="O4" value="-33.7" spread="23.46"/>
                    <measurement group_id="O5" value="-31.7" spread="24.10"/>
                    <measurement group_id="O6" value="-33.9" spread="23.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.1" spread="23.65"/>
                    <measurement group_id="O2" value="-34.1" spread="26.03"/>
                    <measurement group_id="O3" value="-37.2" spread="29.10"/>
                    <measurement group_id="O4" value="-30.7" spread="39.29"/>
                    <measurement group_id="O5" value="-28.5" spread="21.25"/>
                    <measurement group_id="O6" value="-34.9" spread="24.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.5" spread="24.77"/>
                    <measurement group_id="O2" value="-34.9" spread="24.41"/>
                    <measurement group_id="O3" value="-38.2" spread="22.88"/>
                    <measurement group_id="O4" value="-33.0" spread="39.17"/>
                    <measurement group_id="O5" value="-28.7" spread="23.22"/>
                    <measurement group_id="O6" value="-35.6" spread="26.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.0" spread="24.63"/>
                    <measurement group_id="O2" value="-35.2" spread="28.60"/>
                    <measurement group_id="O3" value="-36.8" spread="23.09"/>
                    <measurement group_id="O4" value="-29.6" spread="32.56"/>
                    <measurement group_id="O5" value="-34.9" spread="25.24"/>
                    <measurement group_id="O6" value="-32.1" spread="28.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician's Global Assessment of Arthritis at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The blinded assessor assessed the participant's overall arthritis appears at the time of each visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (very good) and 100 (very poor). VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, and a negative change from baseline represents improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Global Assessment of Arthritis at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The blinded assessor assessed the participant's overall arthritis appears at the time of each visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (very good) and 100 (very poor). VAS data was rescaled prior to any calculation and analysis. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). The score range was 0 mm to 100 mm, and a negative change from baseline represents improvement.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="15.59"/>
                    <measurement group_id="O2" value="-9.0" spread="14.87"/>
                    <measurement group_id="O3" value="-9.9" spread="14.55"/>
                    <measurement group_id="O4" value="-1.9" spread="10.79"/>
                    <measurement group_id="O5" value="-3.4" spread="11.92"/>
                    <measurement group_id="O6" value="-7.2" spread="13.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.8" spread="18.98"/>
                    <measurement group_id="O2" value="-17.6" spread="18.37"/>
                    <measurement group_id="O3" value="-18.3" spread="22.31"/>
                    <measurement group_id="O4" value="-11.1" spread="13.99"/>
                    <measurement group_id="O5" value="-8.8" spread="17.67"/>
                    <measurement group_id="O6" value="-9.5" spread="18.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.6" spread="19.43"/>
                    <measurement group_id="O2" value="-25.0" spread="18.02"/>
                    <measurement group_id="O3" value="-28.7" spread="15.73"/>
                    <measurement group_id="O4" value="-16.4" spread="21.08"/>
                    <measurement group_id="O5" value="-16.3" spread="20.97"/>
                    <measurement group_id="O6" value="-11.9" spread="17.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.2" spread="19.92"/>
                    <measurement group_id="O2" value="-30.1" spread="16.85"/>
                    <measurement group_id="O3" value="-31.1" spread="20.62"/>
                    <measurement group_id="O4" value="-21.2" spread="22.01"/>
                    <measurement group_id="O5" value="-16.5" spread="21.57"/>
                    <measurement group_id="O6" value="-13.7" spread="22.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.7" spread="20.59"/>
                    <measurement group_id="O2" value="-33.7" spread="17.89"/>
                    <measurement group_id="O3" value="-31.2" spread="20.00"/>
                    <measurement group_id="O4" value="-32.5" spread="23.98"/>
                    <measurement group_id="O5" value="-16.5" spread="23.34"/>
                    <measurement group_id="O6" value="-14.4" spread="27.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.8" spread="19.91"/>
                    <measurement group_id="O2" value="-37.8" spread="19.48"/>
                    <measurement group_id="O3" value="-38.7" spread="24.67"/>
                    <measurement group_id="O4" value="-34.7" spread="26.16"/>
                    <measurement group_id="O5" value="-31.0" spread="22.29"/>
                    <measurement group_id="O6" value="-27.1" spread="25.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.0" spread="21.42"/>
                    <measurement group_id="O2" value="-36.7" spread="21.91"/>
                    <measurement group_id="O3" value="-47.6" spread="21.44"/>
                    <measurement group_id="O4" value="-42.4" spread="23.28"/>
                    <measurement group_id="O5" value="-32.7" spread="22.03"/>
                    <measurement group_id="O6" value="-38.8" spread="20.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.7" spread="22.92"/>
                    <measurement group_id="O2" value="-36.8" spread="23.05"/>
                    <measurement group_id="O3" value="-46.3" spread="22.42"/>
                    <measurement group_id="O4" value="-43.4" spread="20.30"/>
                    <measurement group_id="O5" value="-38.0" spread="19.52"/>
                    <measurement group_id="O6" value="-42.6" spread="20.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.5" spread="20.15"/>
                    <measurement group_id="O2" value="-40.6" spread="22.19"/>
                    <measurement group_id="O3" value="-51.9" spread="15.81"/>
                    <measurement group_id="O4" value="-43.2" spread="25.55"/>
                    <measurement group_id="O5" value="-36.4" spread="20.54"/>
                    <measurement group_id="O6" value="-44.9" spread="20.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.6" spread="21.73"/>
                    <measurement group_id="O2" value="-43.4" spread="20.36"/>
                    <measurement group_id="O3" value="-54.1" spread="15.18"/>
                    <measurement group_id="O4" value="-42.7" spread="23.34"/>
                    <measurement group_id="O5" value="-36.3" spread="21.01"/>
                    <measurement group_id="O6" value="-41.9" spread="22.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index (DI) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The HAQ-DI assessed the degree of difficulty a participant experienced in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question in the questionnaire, the level of difficulty is scored from 0 to 3 with 0 representing &quot;no difficulty,&quot; 1 as &quot;some difficulty,&quot; 2 as &quot;much difficulty,&quot; and 3 as &quot;unable to do&quot;. Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range was 0 to 3, with a higher score indicating more difficulty in performing daily living activities. A negative change from baseline represents improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index (DI) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The HAQ-DI assessed the degree of difficulty a participant experienced in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question in the questionnaire, the level of difficulty is scored from 0 to 3 with 0 representing &quot;no difficulty,&quot; 1 as &quot;some difficulty,&quot; 2 as &quot;much difficulty,&quot; and 3 as &quot;unable to do&quot;. Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range was 0 to 3, with a higher score indicating more difficulty in performing daily living activities. A negative change from baseline represents improvement.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.133" spread="0.4273"/>
                    <measurement group_id="O2" value="-0.177" spread="0.3489"/>
                    <measurement group_id="O3" value="-0.195" spread="0.2886"/>
                    <measurement group_id="O4" value="-0.117" spread="0.4212"/>
                    <measurement group_id="O5" value="-0.030" spread="0.4572"/>
                    <measurement group_id="O6" value="-0.170" spread="0.3091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.248" spread="0.5341"/>
                    <measurement group_id="O2" value="-0.315" spread="0.3777"/>
                    <measurement group_id="O3" value="-0.180" spread="0.2090"/>
                    <measurement group_id="O4" value="-0.217" spread="0.3356"/>
                    <measurement group_id="O5" value="-0.095" spread="0.4931"/>
                    <measurement group_id="O6" value="-0.170" spread="0.3305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.343" spread="0.5690"/>
                    <measurement group_id="O2" value="-0.421" spread="0.4103"/>
                    <measurement group_id="O3" value="-0.188" spread="0.4472"/>
                    <measurement group_id="O4" value="-0.277" spread="0.3609"/>
                    <measurement group_id="O5" value="-0.184" spread="0.4959"/>
                    <measurement group_id="O6" value="-0.249" spread="0.4465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.366" spread="0.5701"/>
                    <measurement group_id="O2" value="-0.478" spread="0.4167"/>
                    <measurement group_id="O3" value="-0.214" spread="0.4230"/>
                    <measurement group_id="O4" value="-0.304" spread="0.2930"/>
                    <measurement group_id="O5" value="-0.121" spread="0.4910"/>
                    <measurement group_id="O6" value="-0.239" spread="0.4660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.474" spread="0.5158"/>
                    <measurement group_id="O2" value="-0.509" spread="0.3994"/>
                    <measurement group_id="O3" value="-0.321" spread="0.3914"/>
                    <measurement group_id="O4" value="-0.375" spread="0.3385"/>
                    <measurement group_id="O5" value="-0.109" spread="0.5271"/>
                    <measurement group_id="O6" value="-0.246" spread="0.3729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.466" spread="0.5546"/>
                    <measurement group_id="O2" value="-0.576" spread="0.4906"/>
                    <measurement group_id="O3" value="-0.404" spread="0.4681"/>
                    <measurement group_id="O4" value="-0.308" spread="0.4610"/>
                    <measurement group_id="O5" value="-0.363" spread="0.4983"/>
                    <measurement group_id="O6" value="-0.472" spread="0.4934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.524" spread="0.5412"/>
                    <measurement group_id="O2" value="-0.583" spread="0.5262"/>
                    <measurement group_id="O3" value="-0.519" spread="0.4531"/>
                    <measurement group_id="O4" value="-0.490" spread="0.5064"/>
                    <measurement group_id="O5" value="-0.422" spread="0.4811"/>
                    <measurement group_id="O6" value="-0.517" spread="0.5520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.520" spread="0.6051"/>
                    <measurement group_id="O2" value="-0.594" spread="0.4990"/>
                    <measurement group_id="O3" value="-0.577" spread="0.5740"/>
                    <measurement group_id="O4" value="-0.519" spread="0.5633"/>
                    <measurement group_id="O5" value="-0.329" spread="0.3816"/>
                    <measurement group_id="O6" value="-0.547" spread="0.5867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.521" spread="0.6197"/>
                    <measurement group_id="O2" value="-0.581" spread="0.5321"/>
                    <measurement group_id="O3" value="-0.563" spread="0.3830"/>
                    <measurement group_id="O4" value="-0.510" spread="0.5576"/>
                    <measurement group_id="O5" value="-0.370" spread="0.4210"/>
                    <measurement group_id="O6" value="-0.576" spread="0.5757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.503" spread="0.6023"/>
                    <measurement group_id="O2" value="-0.567" spread="0.4866"/>
                    <measurement group_id="O3" value="-0.500" spread="0.5137"/>
                    <measurement group_id="O4" value="-0.552" spread="0.5041"/>
                    <measurement group_id="O5" value="-0.411" spread="0.3695"/>
                    <measurement group_id="O6" value="-0.514" spread="0.5704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>C-reactive protein (hsCRP) is an acute phase reactant, which is indicative of inflammation and of its severity. Blood samples were obtained at Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52 for determination of hsCRP.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; included all the participants in the pharmacodynamic (PD) analysis population who received at least one dose of randomized study treatment and in whom at least one value of the PD parameter of interest was reported. &quot;Number Analyzed&quot; included participants available in the PD analysis population at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>C-reactive protein (hsCRP) is an acute phase reactant, which is indicative of inflammation and of its severity. Blood samples were obtained at Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52 for determination of hsCRP.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; included all the participants in the pharmacodynamic (PD) analysis population who received at least one dose of randomized study treatment and in whom at least one value of the PD parameter of interest was reported. &quot;Number Analyzed&quot; included participants available in the PD analysis population at each specified visit.</population>
          <units>milligram per liter (mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.420" spread="8.9409"/>
                    <measurement group_id="O2" value="-3.696" spread="11.9628"/>
                    <measurement group_id="O3" value="-6.023" spread="19.1126"/>
                    <measurement group_id="O4" value="-0.595" spread="1.4661"/>
                    <measurement group_id="O5" value="-1.641" spread="10.4224"/>
                    <measurement group_id="O6" value="1.462" spread="7.8966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.645" spread="11.8144"/>
                    <measurement group_id="O2" value="-5.543" spread="11.9617"/>
                    <measurement group_id="O3" value="-6.134" spread="19.5633"/>
                    <measurement group_id="O4" value="-1.324" spread="1.9735"/>
                    <measurement group_id="O5" value="0.010" spread="7.0206"/>
                    <measurement group_id="O6" value="1.206" spread="5.4423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.828" spread="10.8093"/>
                    <measurement group_id="O2" value="-5.102" spread="11.5408"/>
                    <measurement group_id="O3" value="-6.029" spread="19.9534"/>
                    <measurement group_id="O4" value="-0.573" spread="2.6595"/>
                    <measurement group_id="O5" value="-2.598" spread="10.7270"/>
                    <measurement group_id="O6" value="0.927" spread="6.2062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.759" spread="11.0481"/>
                    <measurement group_id="O2" value="-5.881" spread="12.9484"/>
                    <measurement group_id="O3" value="-7.335" spread="22.0149"/>
                    <measurement group_id="O4" value="-1.177" spread="3.4854"/>
                    <measurement group_id="O5" value="-1.061" spread="11.1944"/>
                    <measurement group_id="O6" value="1.021" spread="6.6025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.695" spread="8.1064"/>
                    <measurement group_id="O2" value="-5.809" spread="13.6463"/>
                    <measurement group_id="O3" value="-5.420" spread="21.9622"/>
                    <measurement group_id="O4" value="1.060" spread="8.7842"/>
                    <measurement group_id="O5" value="-2.218" spread="11.6164"/>
                    <measurement group_id="O6" value="-0.762" spread="6.5779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.581" spread="10.5026"/>
                    <measurement group_id="O2" value="-6.014" spread="14.7723"/>
                    <measurement group_id="O3" value="-7.879" spread="24.2763"/>
                    <measurement group_id="O4" value="-0.989" spread="3.6969"/>
                    <measurement group_id="O5" value="-5.982" spread="10.4711"/>
                    <measurement group_id="O6" value="-4.718" spread="7.1896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.277" spread="12.9069"/>
                    <measurement group_id="O2" value="-6.362" spread="13.6372"/>
                    <measurement group_id="O3" value="-8.679" spread="24.9759"/>
                    <measurement group_id="O4" value="-1.300" spread="3.7971"/>
                    <measurement group_id="O5" value="-6.112" spread="10.6756"/>
                    <measurement group_id="O6" value="-5.484" spread="10.0475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.899" spread="10.3015"/>
                    <measurement group_id="O2" value="-5.940" spread="14.4219"/>
                    <measurement group_id="O3" value="-9.461" spread="25.7767"/>
                    <measurement group_id="O4" value="-1.814" spread="3.0658"/>
                    <measurement group_id="O5" value="-6.247" spread="9.8145"/>
                    <measurement group_id="O6" value="-5.029" spread="9.1947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.543" spread="11.7058"/>
                    <measurement group_id="O2" value="-6.215" spread="14.2493"/>
                    <measurement group_id="O3" value="-2.196" spread="2.2859"/>
                    <measurement group_id="O4" value="-0.987" spread="3.7325"/>
                    <measurement group_id="O5" value="-4.690" spread="9.9495"/>
                    <measurement group_id="O6" value="-0.711" spread="13.7530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.167" spread="13.3963"/>
                    <measurement group_id="O2" value="-4.880" spread="14.1148"/>
                    <measurement group_id="O3" value="-1.586" spread="3.0576"/>
                    <measurement group_id="O4" value="-2.028" spread="3.2177"/>
                    <measurement group_id="O5" value="-4.324" spread="7.7335"/>
                    <measurement group_id="O6" value="-4.722" spread="9.3318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 indicates a 75% or greater reduction in PASI scores from baseline.</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; included a subgroup of participants in the evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline BSA ≥3% and PASI &gt;0 . &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit with baseline BSA ≥3% and PASI &gt;0.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 indicates a 75% or greater reduction in PASI scores from baseline.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; included a subgroup of participants in the evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline BSA ≥3% and PASI &gt;0 . &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit with baseline BSA ≥3% and PASI &gt;0.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="0.00" upper_limit="11.75"/>
                    <measurement group_id="O2" value="2.56" lower_limit="0.00" upper_limit="7.52"/>
                    <measurement group_id="O3" value="3.85" lower_limit="0.00" upper_limit="14.30"/>
                    <measurement group_id="O4" value="11.11" lower_limit="0.00" upper_limit="31.64"/>
                    <measurement group_id="O5" value="2.17" lower_limit="0.00" upper_limit="8.13"/>
                    <measurement group_id="O6" value="5.26" lower_limit="0.00" upper_limit="15.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.00" lower_limit="15.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="12.82" lower_limit="2.33" upper_limit="23.31"/>
                    <measurement group_id="O3" value="3.85" lower_limit="0.00" upper_limit="14.30"/>
                    <measurement group_id="O4" value="11.11" lower_limit="0.00" upper_limit="31.64"/>
                    <measurement group_id="O5" value="4.55" lower_limit="0.00" upper_limit="13.25"/>
                    <measurement group_id="O6" value="5.26" lower_limit="0.00" upper_limit="15.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.00" lower_limit="29.58" upper_limit="60.42"/>
                    <measurement group_id="O2" value="41.03" lower_limit="25.59" upper_limit="56.46"/>
                    <measurement group_id="O3" value="25.00" lower_limit="0.50" upper_limit="49.50"/>
                    <measurement group_id="O4" value="11.11" lower_limit="0.00" upper_limit="31.64"/>
                    <measurement group_id="O5" value="9.09" lower_limit="0.00" upper_limit="21.10"/>
                    <measurement group_id="O6" value="15.79" lower_limit="0.00" upper_limit="32.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00" lower_limit="44.82" upper_limit="75.18"/>
                    <measurement group_id="O2" value="48.72" lower_limit="33.03" upper_limit="64.41"/>
                    <measurement group_id="O3" value="33.33" lower_limit="6.66" upper_limit="60.01"/>
                    <measurement group_id="O4" value="33.33" lower_limit="2.54" upper_limit="64.13"/>
                    <measurement group_id="O5" value="18.18" lower_limit="2.06" upper_limit="34.30"/>
                    <measurement group_id="O6" value="21.05" lower_limit="2.72" upper_limit="39.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.23" lower_limit="54.75" upper_limit="83.72"/>
                    <measurement group_id="O2" value="58.97" lower_limit="43.54" upper_limit="74.41"/>
                    <measurement group_id="O3" value="58.33" lower_limit="30.44" upper_limit="86.23"/>
                    <measurement group_id="O4" value="55.56" lower_limit="23.09" upper_limit="88.02"/>
                    <measurement group_id="O5" value="22.73" lower_limit="5.22" upper_limit="40.24"/>
                    <measurement group_id="O6" value="26.32" lower_limit="6.52" upper_limit="46.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.50" lower_limit="58.66" upper_limit="86.34"/>
                    <measurement group_id="O2" value="61.54" lower_limit="46.27" upper_limit="76.81"/>
                    <measurement group_id="O3" value="66.67" lower_limit="39.99" upper_limit="93.34"/>
                    <measurement group_id="O4" value="55.56" lower_limit="23.09" upper_limit="88.02"/>
                    <measurement group_id="O5" value="54.55" lower_limit="33.74" upper_limit="75.35"/>
                    <measurement group_id="O6" value="36.84" lower_limit="15.15" upper_limit="58.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.00" lower_limit="55.80" upper_limit="84.20"/>
                    <measurement group_id="O2" value="51.28" lower_limit="35.59" upper_limit="66.97"/>
                    <measurement group_id="O3" value="91.67" lower_limit="76.03" upper_limit="100.00"/>
                    <measurement group_id="O4" value="77.78" lower_limit="50.62" upper_limit="100.00"/>
                    <measurement group_id="O5" value="63.64" lower_limit="43.54" upper_limit="83.74"/>
                    <measurement group_id="O6" value="63.16" lower_limit="41.47" upper_limit="84.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.00" lower_limit="55.80" upper_limit="84.20"/>
                    <measurement group_id="O2" value="64.10" lower_limit="49.05" upper_limit="79.16"/>
                    <measurement group_id="O3" value="96.15" lower_limit="85.70" upper_limit="100.00"/>
                    <measurement group_id="O4" value="88.89" lower_limit="68.36" upper_limit="100.00"/>
                    <measurement group_id="O5" value="59.09" lower_limit="38.55" upper_limit="79.64"/>
                    <measurement group_id="O6" value="47.37" lower_limit="24.92" upper_limit="69.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00" lower_limit="61.58" upper_limit="88.42"/>
                    <measurement group_id="O2" value="66.67" lower_limit="51.87" upper_limit="81.46"/>
                    <measurement group_id="O3" value="75.00" lower_limit="50.50" upper_limit="99.50"/>
                    <measurement group_id="O4" value="55.56" lower_limit="23.09" upper_limit="88.02"/>
                    <measurement group_id="O5" value="63.64" lower_limit="43.54" upper_limit="83.74"/>
                    <measurement group_id="O6" value="63.16" lower_limit="41.47" upper_limit="84.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.00" lower_limit="50.22" upper_limit="79.78"/>
                    <measurement group_id="O2" value="66.67" lower_limit="51.87" upper_limit="81.46"/>
                    <measurement group_id="O3" value="66.67" lower_limit="39.99" upper_limit="93.34"/>
                    <measurement group_id="O4" value="66.67" lower_limit="35.87" upper_limit="97.46"/>
                    <measurement group_id="O5" value="50.00" lower_limit="29.11" upper_limit="70.89"/>
                    <measurement group_id="O6" value="57.89" lower_limit="35.69" upper_limit="80.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a PASI 90 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 indicates a 90% or greater reduction in PASI scores from baseline.</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; included a subgroup of participants in the evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline BSA ≥3% and PASI &gt;0 . &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit with baseline BSA ≥3% and PASI &gt;0.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a PASI 90 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 indicates a 90% or greater reduction in PASI scores from baseline.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; included a subgroup of participants in the evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline BSA ≥3% and PASI &gt;0 . &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit with baseline BSA ≥3% and PASI &gt;0.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" lower_limit="0.00" upper_limit="4.58"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.00" upper_limit="4.69"/>
                    <measurement group_id="O3" value="3.85" lower_limit="0.00" upper_limit="14.30"/>
                    <measurement group_id="O4" value="11.11" lower_limit="0.00" upper_limit="31.64"/>
                    <measurement group_id="O5" value="2.17" lower_limit="0.00" upper_limit="8.13"/>
                    <measurement group_id="O6" value="2.50" lower_limit="0.00" upper_limit="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.50" lower_limit="5.72" upper_limit="29.28"/>
                    <measurement group_id="O2" value="5.13" lower_limit="0.00" upper_limit="12.05"/>
                    <measurement group_id="O3" value="3.85" lower_limit="0.00" upper_limit="14.30"/>
                    <measurement group_id="O4" value="11.11" lower_limit="0.00" upper_limit="31.64"/>
                    <measurement group_id="O5" value="4.55" lower_limit="0.00" upper_limit="13.25"/>
                    <measurement group_id="O6" value="2.50" lower_limit="0.00" upper_limit="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.00" lower_limit="20.22" upper_limit="49.78"/>
                    <measurement group_id="O2" value="17.95" lower_limit="5.90" upper_limit="29.99"/>
                    <measurement group_id="O3" value="16.67" lower_limit="0.00" upper_limit="37.75"/>
                    <measurement group_id="O4" value="11.11" lower_limit="0.00" upper_limit="31.64"/>
                    <measurement group_id="O5" value="2.17" lower_limit="0.00" upper_limit="8.13"/>
                    <measurement group_id="O6" value="5.26" lower_limit="0.00" upper_limit="15.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.50" lower_limit="32.02" upper_limit="62.98"/>
                    <measurement group_id="O2" value="25.64" lower_limit="11.94" upper_limit="39.35"/>
                    <measurement group_id="O3" value="16.67" lower_limit="0.00" upper_limit="37.75"/>
                    <measurement group_id="O4" value="22.22" lower_limit="0.00" upper_limit="49.38"/>
                    <measurement group_id="O5" value="2.17" lower_limit="0.00" upper_limit="8.13"/>
                    <measurement group_id="O6" value="10.53" lower_limit="0.00" upper_limit="24.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.85" lower_limit="38.20" upper_limit="69.49"/>
                    <measurement group_id="O2" value="33.33" lower_limit="18.54" upper_limit="48.13"/>
                    <measurement group_id="O3" value="33.33" lower_limit="6.66" upper_limit="60.01"/>
                    <measurement group_id="O4" value="33.33" lower_limit="2.54" upper_limit="64.13"/>
                    <measurement group_id="O5" value="9.09" lower_limit="0.00" upper_limit="21.10"/>
                    <measurement group_id="O6" value="15.79" lower_limit="0.00" upper_limit="32.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00" lower_limit="34.51" upper_limit="65.49"/>
                    <measurement group_id="O2" value="43.59" lower_limit="28.03" upper_limit="59.15"/>
                    <measurement group_id="O3" value="50.00" lower_limit="21.71" upper_limit="78.29"/>
                    <measurement group_id="O4" value="44.44" lower_limit="11.98" upper_limit="76.91"/>
                    <measurement group_id="O5" value="18.18" lower_limit="2.06" upper_limit="34.30"/>
                    <measurement group_id="O6" value="26.32" lower_limit="6.52" upper_limit="46.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.50" lower_limit="37.02" upper_limit="67.98"/>
                    <measurement group_id="O2" value="38.46" lower_limit="23.19" upper_limit="53.73"/>
                    <measurement group_id="O3" value="58.33" lower_limit="30.44" upper_limit="86.23"/>
                    <measurement group_id="O4" value="44.44" lower_limit="11.98" upper_limit="76.91"/>
                    <measurement group_id="O5" value="50.00" lower_limit="29.11" upper_limit="70.89"/>
                    <measurement group_id="O6" value="31.58" lower_limit="10.68" upper_limit="52.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.50" lower_limit="47.50" upper_limit="77.50"/>
                    <measurement group_id="O2" value="48.72" lower_limit="33.03" upper_limit="64.41"/>
                    <measurement group_id="O3" value="83.33" lower_limit="62.25" upper_limit="100.00"/>
                    <measurement group_id="O4" value="66.67" lower_limit="35.87" upper_limit="97.46"/>
                    <measurement group_id="O5" value="45.45" lower_limit="24.65" upper_limit="66.26"/>
                    <measurement group_id="O6" value="36.84" lower_limit="15.15" upper_limit="58.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.50" lower_limit="37.02" upper_limit="67.98"/>
                    <measurement group_id="O2" value="48.72" lower_limit="33.03" upper_limit="64.41"/>
                    <measurement group_id="O3" value="66.67" lower_limit="39.99" upper_limit="93.34"/>
                    <measurement group_id="O4" value="44.44" lower_limit="11.98" upper_limit="76.91"/>
                    <measurement group_id="O5" value="50.00" lower_limit="29.11" upper_limit="70.89"/>
                    <measurement group_id="O6" value="52.63" lower_limit="30.18" upper_limit="75.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.00" lower_limit="24.82" upper_limit="55.18"/>
                    <measurement group_id="O2" value="56.41" lower_limit="40.85" upper_limit="71.97"/>
                    <measurement group_id="O3" value="66.67" lower_limit="39.99" upper_limit="93.34"/>
                    <measurement group_id="O4" value="55.56" lower_limit="23.09" upper_limit="88.02"/>
                    <measurement group_id="O5" value="45.45" lower_limit="24.65" upper_limit="66.26"/>
                    <measurement group_id="O6" value="47.37" lower_limit="24.92" upper_limit="69.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a PASI 100 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 100 indicates a 100% reduction in PASI scores from baseline.</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; included a subgroup of participants in the evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline BSA ≥3% and PASI &gt;0 . &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit with baseline BSA ≥3% and PASI &gt;0.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a PASI 100 Response at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 100 indicates a 100% reduction in PASI scores from baseline.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; included a subgroup of participants in the evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline BSA ≥3% and PASI &gt;0 . &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit with baseline BSA ≥3% and PASI &gt;0.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" lower_limit="0.00" upper_limit="4.58"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.00" upper_limit="4.69"/>
                    <measurement group_id="O3" value="3.85" lower_limit="0.00" upper_limit="14.30"/>
                    <measurement group_id="O4" value="11.11" lower_limit="0.00" upper_limit="31.64"/>
                    <measurement group_id="O5" value="2.17" lower_limit="0.00" upper_limit="8.13"/>
                    <measurement group_id="O6" value="2.50" lower_limit="0.00" upper_limit="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.50" lower_limit="0.00" upper_limit="15.66"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.00" upper_limit="4.69"/>
                    <measurement group_id="O3" value="3.85" lower_limit="0.00" upper_limit="14.30"/>
                    <measurement group_id="O4" value="5.00" lower_limit="0.00" upper_limit="18.51"/>
                    <measurement group_id="O5" value="4.55" lower_limit="0.00" upper_limit="13.25"/>
                    <measurement group_id="O6" value="2.50" lower_limit="0.00" upper_limit="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00" lower_limit="7.60" upper_limit="32.40"/>
                    <measurement group_id="O2" value="5.13" lower_limit="0.00" upper_limit="12.05"/>
                    <measurement group_id="O3" value="8.33" lower_limit="0.00" upper_limit="23.97"/>
                    <measurement group_id="O4" value="11.11" lower_limit="0.00" upper_limit="31.64"/>
                    <measurement group_id="O5" value="2.17" lower_limit="0.00" upper_limit="8.13"/>
                    <measurement group_id="O6" value="2.50" lower_limit="0.00" upper_limit="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.00" lower_limit="20.22" upper_limit="49.78"/>
                    <measurement group_id="O2" value="7.69" lower_limit="0.00" upper_limit="16.06"/>
                    <measurement group_id="O3" value="8.33" lower_limit="0.00" upper_limit="23.97"/>
                    <measurement group_id="O4" value="11.11" lower_limit="0.00" upper_limit="31.64"/>
                    <measurement group_id="O5" value="2.17" lower_limit="0.00" upper_limit="8.13"/>
                    <measurement group_id="O6" value="5.26" lower_limit="0.00" upper_limit="15.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.90" lower_limit="20.84" upper_limit="50.95"/>
                    <measurement group_id="O2" value="15.38" lower_limit="4.06" upper_limit="26.71"/>
                    <measurement group_id="O3" value="16.67" lower_limit="0.00" upper_limit="37.75"/>
                    <measurement group_id="O4" value="33.33" lower_limit="2.54" upper_limit="64.13"/>
                    <measurement group_id="O5" value="9.09" lower_limit="0.00" upper_limit="21.10"/>
                    <measurement group_id="O6" value="10.53" lower_limit="0.00" upper_limit="24.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.50" lower_limit="13.66" upper_limit="41.34"/>
                    <measurement group_id="O2" value="35.90" lower_limit="20.84" upper_limit="50.95"/>
                    <measurement group_id="O3" value="33.33" lower_limit="6.66" upper_limit="60.01"/>
                    <measurement group_id="O4" value="44.44" lower_limit="11.98" upper_limit="76.91"/>
                    <measurement group_id="O5" value="13.64" lower_limit="0.00" upper_limit="27.98"/>
                    <measurement group_id="O6" value="10.53" lower_limit="0.00" upper_limit="24.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.00" lower_limit="20.22" upper_limit="49.78"/>
                    <measurement group_id="O2" value="30.77" lower_limit="16.28" upper_limit="45.25"/>
                    <measurement group_id="O3" value="50.00" lower_limit="21.71" upper_limit="78.29"/>
                    <measurement group_id="O4" value="44.44" lower_limit="11.98" upper_limit="76.91"/>
                    <measurement group_id="O5" value="40.91" lower_limit="20.36" upper_limit="61.45"/>
                    <measurement group_id="O6" value="21.05" lower_limit="2.72" upper_limit="39.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.00" lower_limit="24.82" upper_limit="55.18"/>
                    <measurement group_id="O2" value="35.90" lower_limit="20.84" upper_limit="50.95"/>
                    <measurement group_id="O3" value="50.00" lower_limit="21.71" upper_limit="78.29"/>
                    <measurement group_id="O4" value="55.56" lower_limit="23.09" upper_limit="88.02"/>
                    <measurement group_id="O5" value="36.36" lower_limit="16.26" upper_limit="56.46"/>
                    <measurement group_id="O6" value="21.05" lower_limit="2.72" upper_limit="39.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.00" lower_limit="15.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="41.03" lower_limit="25.59" upper_limit="56.46"/>
                    <measurement group_id="O3" value="58.33" lower_limit="30.44" upper_limit="86.23"/>
                    <measurement group_id="O4" value="44.44" lower_limit="11.98" upper_limit="76.91"/>
                    <measurement group_id="O5" value="31.82" lower_limit="12.36" upper_limit="51.28"/>
                    <measurement group_id="O6" value="42.11" lower_limit="19.90" upper_limit="64.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.00" lower_limit="20.22" upper_limit="49.78"/>
                    <measurement group_id="O2" value="38.46" lower_limit="23.19" upper_limit="53.73"/>
                    <measurement group_id="O3" value="41.67" lower_limit="13.77" upper_limit="69.56"/>
                    <measurement group_id="O4" value="33.33" lower_limit="2.54" upper_limit="64.13"/>
                    <measurement group_id="O5" value="36.36" lower_limit="16.26" upper_limit="56.46"/>
                    <measurement group_id="O6" value="42.11" lower_limit="19.90" upper_limit="64.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Enthesitis Score (Using the Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The SPARCC Enthesitis Index examines tenderness at sixteen sites: medial epicondyle humerus, lateral epicondyle humerus, supraspinatus insertion into greater tuberosity of humerus, greater trochanter, quadriceps insertion into superior border of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle (considered 1 site for scoring purposes), Achilles tendon insertion into calcaneum and plantar fascia insertion into calcaneum. Each site is classified on a dichotomous basis as either tender (score=1) or not tender (score=0). The SPARCC Enthesitis Index scores range from 0-16, with higher scores indicating higher disease activity.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; included all the participants in the evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline SPARCC enthesitis score&gt;0. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints with baseline SPARCC enthesitis score &gt;0.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Enthesitis Score (Using the Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The SPARCC Enthesitis Index examines tenderness at sixteen sites: medial epicondyle humerus, lateral epicondyle humerus, supraspinatus insertion into greater tuberosity of humerus, greater trochanter, quadriceps insertion into superior border of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle (considered 1 site for scoring purposes), Achilles tendon insertion into calcaneum and plantar fascia insertion into calcaneum. Each site is classified on a dichotomous basis as either tender (score=1) or not tender (score=0). The SPARCC Enthesitis Index scores range from 0-16, with higher scores indicating higher disease activity.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; included all the participants in the evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline SPARCC enthesitis score&gt;0. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints with baseline SPARCC enthesitis score &gt;0.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.55"/>
                    <measurement group_id="O2" value="-0.3" spread="2.73"/>
                    <measurement group_id="O3" value="-1.4" spread="1.86"/>
                    <measurement group_id="O4" value="0.0" spread="1.12"/>
                    <measurement group_id="O5" value="-0.2" spread="1.79"/>
                    <measurement group_id="O6" value="-0.3" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.41"/>
                    <measurement group_id="O2" value="-0.9" spread="2.32"/>
                    <measurement group_id="O3" value="-1.3" spread="2.37"/>
                    <measurement group_id="O4" value="0.0" spread="1.41"/>
                    <measurement group_id="O5" value="-1.0" spread="2.29"/>
                    <measurement group_id="O6" value="-1.0" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="2.11"/>
                    <measurement group_id="O2" value="-1.9" spread="2.23"/>
                    <measurement group_id="O3" value="-1.4" spread="1.80"/>
                    <measurement group_id="O4" value="-1.0" spread="1.07"/>
                    <measurement group_id="O5" value="-1.1" spread="2.50"/>
                    <measurement group_id="O6" value="-1.2" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="2.49"/>
                    <measurement group_id="O2" value="-1.6" spread="2.22"/>
                    <measurement group_id="O3" value="-2.7" spread="1.73"/>
                    <measurement group_id="O4" value="-1.3" spread="1.04"/>
                    <measurement group_id="O5" value="-1.7" spread="2.52"/>
                    <measurement group_id="O6" value="-1.1" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="2.68"/>
                    <measurement group_id="O2" value="-1.3" spread="1.89"/>
                    <measurement group_id="O3" value="-3.1" spread="1.27"/>
                    <measurement group_id="O4" value="-0.3" spread="2.71"/>
                    <measurement group_id="O5" value="-1.8" spread="2.94"/>
                    <measurement group_id="O6" value="-1.2" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="2.66"/>
                    <measurement group_id="O2" value="-1.9" spread="2.29"/>
                    <measurement group_id="O3" value="-3.2" spread="3.03"/>
                    <measurement group_id="O4" value="-1.3" spread="0.89"/>
                    <measurement group_id="O5" value="-2.1" spread="2.24"/>
                    <measurement group_id="O6" value="-1.9" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="2.68"/>
                    <measurement group_id="O2" value="-2.3" spread="2.60"/>
                    <measurement group_id="O3" value="-3.8" spread="2.05"/>
                    <measurement group_id="O4" value="-1.4" spread="1.19"/>
                    <measurement group_id="O5" value="-2.5" spread="2.97"/>
                    <measurement group_id="O6" value="-3.1" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="2.70"/>
                    <measurement group_id="O2" value="-2.3" spread="2.28"/>
                    <measurement group_id="O3" value="-3.8" spread="2.79"/>
                    <measurement group_id="O4" value="-1.6" spread="1.06"/>
                    <measurement group_id="O5" value="-2.1" spread="2.51"/>
                    <measurement group_id="O6" value="-2.8" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="2.56"/>
                    <measurement group_id="O2" value="-2.4" spread="2.53"/>
                    <measurement group_id="O3" value="-3.3" spread="1.67"/>
                    <measurement group_id="O4" value="-1.6" spread="1.06"/>
                    <measurement group_id="O5" value="-2.1" spread="2.57"/>
                    <measurement group_id="O6" value="-3.2" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="2.55"/>
                    <measurement group_id="O2" value="-2.4" spread="2.34"/>
                    <measurement group_id="O3" value="-4.8" spread="2.76"/>
                    <measurement group_id="O4" value="-1.5" spread="0.76"/>
                    <measurement group_id="O5" value="-2.2" spread="1.74"/>
                    <measurement group_id="O6" value="-3.6" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Enthesitis Score (Using the Leeds Enthesitis Index) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The Leeds Enthesitis Index (LEI) examines tenderness at six sites: lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Each site is assessed as either tender (score=1) or not tender (score=0). The LEI scores range from 0-6, with higher scores indicating higher disease activity.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; included all the participants in the evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline leeds enthesitis score&gt;0. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints with baseline leeds enthesitis score&gt;0.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Enthesitis Score (Using the Leeds Enthesitis Index) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The Leeds Enthesitis Index (LEI) examines tenderness at six sites: lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Each site is assessed as either tender (score=1) or not tender (score=0). The LEI scores range from 0-6, with higher scores indicating higher disease activity.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; included all the participants in the evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline leeds enthesitis score&gt;0. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints with baseline leeds enthesitis score&gt;0.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.95"/>
                    <measurement group_id="O2" value="-0.4" spread="1.53"/>
                    <measurement group_id="O3" value="-0.5" spread="1.27"/>
                    <measurement group_id="O4" value="0.0" spread="0.53"/>
                    <measurement group_id="O5" value="-0.1" spread="1.12"/>
                    <measurement group_id="O6" value="-0.3" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.56"/>
                    <measurement group_id="O2" value="-0.9" spread="1.48"/>
                    <measurement group_id="O3" value="-1.0" spread="1.25"/>
                    <measurement group_id="O4" value="-0.1" spread="0.99"/>
                    <measurement group_id="O5" value="-0.4" spread="0.75"/>
                    <measurement group_id="O6" value="-0.9" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.43"/>
                    <measurement group_id="O2" value="-1.2" spread="1.47"/>
                    <measurement group_id="O3" value="-0.5" spread="1.78"/>
                    <measurement group_id="O4" value="-0.4" spread="0.98"/>
                    <measurement group_id="O5" value="-0.5" spread="1.31"/>
                    <measurement group_id="O6" value="-0.7" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.93"/>
                    <measurement group_id="O2" value="-1.5" spread="1.42"/>
                    <measurement group_id="O3" value="-1.0" spread="1.22"/>
                    <measurement group_id="O4" value="-1.1" spread="0.90"/>
                    <measurement group_id="O5" value="-0.9" spread="0.94"/>
                    <measurement group_id="O6" value="-0.9" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.63"/>
                    <measurement group_id="O2" value="-1.5" spread="1.45"/>
                    <measurement group_id="O3" value="-1.2" spread="0.83"/>
                    <measurement group_id="O4" value="-0.1" spread="2.12"/>
                    <measurement group_id="O5" value="-0.9" spread="1.13"/>
                    <measurement group_id="O6" value="-0.9" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.52"/>
                    <measurement group_id="O2" value="-1.3" spread="1.80"/>
                    <measurement group_id="O3" value="-1.7" spread="2.65"/>
                    <measurement group_id="O4" value="-0.9" spread="0.90"/>
                    <measurement group_id="O5" value="-1.1" spread="0.90"/>
                    <measurement group_id="O6" value="-1.4" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.56"/>
                    <measurement group_id="O2" value="-1.7" spread="1.57"/>
                    <measurement group_id="O3" value="-1.9" spread="2.20"/>
                    <measurement group_id="O4" value="-1.3" spread="0.76"/>
                    <measurement group_id="O5" value="-1.1" spread="1.20"/>
                    <measurement group_id="O6" value="-1.7" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="1.36"/>
                    <measurement group_id="O2" value="-1.8" spread="1.59"/>
                    <measurement group_id="O3" value="-2.3" spread="1.50"/>
                    <measurement group_id="O4" value="-1.1" spread="0.90"/>
                    <measurement group_id="O5" value="-1.1" spread="1.17"/>
                    <measurement group_id="O6" value="-1.7" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="1.47"/>
                    <measurement group_id="O2" value="-1.8" spread="1.65"/>
                    <measurement group_id="O3" value="-2.3" spread="1.04"/>
                    <measurement group_id="O4" value="-1.3" spread="0.76"/>
                    <measurement group_id="O5" value="-1.2" spread="1.19"/>
                    <measurement group_id="O6" value="-1.9" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.54"/>
                    <measurement group_id="O2" value="-1.7" spread="1.40"/>
                    <measurement group_id="O3" value="-2.5" spread="0.93"/>
                    <measurement group_id="O4" value="-1.0" spread="0.82"/>
                    <measurement group_id="O5" value="-1.2" spread="0.73"/>
                    <measurement group_id="O6" value="-1.8" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Dactylitis Severity Score (DSS) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The number of digits in hands and feet with dactylitis was evaluated by a blinded assessor. In addition, dactylitis severity was scored based upon digit tenderness using a scale of 0-3, where 0 = no tenderness to 3 = extreme tenderness, in each digit of the hands and feet. The range of total dactylitis scores was 0-60, with higher scores indicating greater severity. A negative change from baseline represents improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; included all the participants in evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline DSS &gt;0. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints with baseline DSS &gt;0.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Dactylitis Severity Score (DSS) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The number of digits in hands and feet with dactylitis was evaluated by a blinded assessor. In addition, dactylitis severity was scored based upon digit tenderness using a scale of 0-3, where 0 = no tenderness to 3 = extreme tenderness, in each digit of the hands and feet. The range of total dactylitis scores was 0-60, with higher scores indicating greater severity. A negative change from baseline represents improvement.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; included all the participants in evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline DSS &gt;0. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints with baseline DSS &gt;0.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.36"/>
                    <measurement group_id="O2" value="-0.7" spread="2.54"/>
                    <measurement group_id="O3" value="-2.7" spread="4.62"/>
                    <measurement group_id="O4" value="-0.5" spread="1.38"/>
                    <measurement group_id="O5" value="-0.7" spread="1.61"/>
                    <measurement group_id="O6" value="0.2" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="3.30"/>
                    <measurement group_id="O2" value="-2.2" spread="3.15"/>
                    <measurement group_id="O3" value="-3.3" spread="3.21"/>
                    <measurement group_id="O4" value="-0.8" spread="1.17"/>
                    <measurement group_id="O5" value="-1.2" spread="2.59"/>
                    <measurement group_id="O6" value="-0.3" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="4.31"/>
                    <measurement group_id="O2" value="-4.0" spread="3.22"/>
                    <measurement group_id="O3" value="-4.3" spread="4.16"/>
                    <measurement group_id="O4" value="-1.7" spread="1.37"/>
                    <measurement group_id="O5" value="-2.5" spread="6.14"/>
                    <measurement group_id="O6" value="-1.8" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="3.34"/>
                    <measurement group_id="O2" value="-4.5" spread="3.30"/>
                    <measurement group_id="O3" value="-4.3" spread="4.93"/>
                    <measurement group_id="O4" value="-3.2" spread="3.43"/>
                    <measurement group_id="O5" value="-4.8" spread="7.07"/>
                    <measurement group_id="O6" value="-2.8" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="3.85"/>
                    <measurement group_id="O2" value="-4.9" spread="4.06"/>
                    <measurement group_id="O3" value="-4.7" spread="6.35"/>
                    <measurement group_id="O4" value="-3.7" spread="4.13"/>
                    <measurement group_id="O5" value="-5.4" spread="7.44"/>
                    <measurement group_id="O6" value="-2.9" spread="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="3.31"/>
                    <measurement group_id="O2" value="-4.6" spread="4.23"/>
                    <measurement group_id="O3" value="-5.3" spread="5.86"/>
                    <measurement group_id="O4" value="-3.7" spread="4.13"/>
                    <measurement group_id="O5" value="-7.0" spread="7.44"/>
                    <measurement group_id="O6" value="-4.4" spread="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="3.67"/>
                    <measurement group_id="O2" value="-5.1" spread="4.08"/>
                    <measurement group_id="O3" value="-5.3" spread="5.86"/>
                    <measurement group_id="O4" value="-3.7" spread="4.13"/>
                    <measurement group_id="O5" value="-6.6" spread="7.18"/>
                    <measurement group_id="O6" value="-4.7" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="4.02"/>
                    <measurement group_id="O2" value="-5.1" spread="4.26"/>
                    <measurement group_id="O3" value="-5.7" spread="5.69"/>
                    <measurement group_id="O4" value="-3.7" spread="4.13"/>
                    <measurement group_id="O5" value="-6.8" spread="7.34"/>
                    <measurement group_id="O6" value="-5.3" spread="7.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="3.65"/>
                    <measurement group_id="O2" value="-5.4" spread="4.01"/>
                    <measurement group_id="O3" value="-5.7" spread="5.69"/>
                    <measurement group_id="O4" value="-3.7" spread="4.13"/>
                    <measurement group_id="O5" value="-6.8" spread="7.34"/>
                    <measurement group_id="O6" value="-5.3" spread="7.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="3.65"/>
                    <measurement group_id="O2" value="-5.4" spread="4.05"/>
                    <measurement group_id="O3" value="-5.7" spread="5.69"/>
                    <measurement group_id="O4" value="-3.7" spread="4.13"/>
                    <measurement group_id="O5" value="-5.0" spread="5.40"/>
                    <measurement group_id="O6" value="-5.7" spread="8.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Nail Psoriasis Severity Index (NAPSI) Score at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>A target finger nail was evaluated by the blinded assessor using the NAPSI scale. At the baseline visit, the worst case fingernail was chosen and the same nail was evaluated consistently through the entire study. Each quadrant of the target nail was graded for nail matrix psoriasis (including any of the following parameters: pitting, leukonychia, red spots in lunula, nail plate crumbling) and nail bed psoriasis (including any of the following parameters: onycholysis, splinter hemorrhages, oil drop (salmon patch) discoloration, nail bed hyperkeratosis). The target nail NAPSI scores range from 0 to 8, with higher scores indicating higher disease activity.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; included all the participants in evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline NAPSI&gt;0. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints with baseline NAPSI&gt;0.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Nail Psoriasis Severity Index (NAPSI) Score at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>A target finger nail was evaluated by the blinded assessor using the NAPSI scale. At the baseline visit, the worst case fingernail was chosen and the same nail was evaluated consistently through the entire study. Each quadrant of the target nail was graded for nail matrix psoriasis (including any of the following parameters: pitting, leukonychia, red spots in lunula, nail plate crumbling) and nail bed psoriasis (including any of the following parameters: onycholysis, splinter hemorrhages, oil drop (salmon patch) discoloration, nail bed hyperkeratosis). The target nail NAPSI scores range from 0 to 8, with higher scores indicating higher disease activity.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; included all the participants in evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline NAPSI&gt;0. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints with baseline NAPSI&gt;0.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.55"/>
                    <measurement group_id="O2" value="0.1" spread="0.65"/>
                    <measurement group_id="O3" value="-0.4" spread="0.52"/>
                    <measurement group_id="O4" value="0.3" spread="0.71"/>
                    <measurement group_id="O5" value="-0.2" spread="1.04"/>
                    <measurement group_id="O6" value="0.1" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.09"/>
                    <measurement group_id="O2" value="-0.5" spread="1.70"/>
                    <measurement group_id="O3" value="-0.9" spread="1.10"/>
                    <measurement group_id="O4" value="-0.3" spread="0.46"/>
                    <measurement group_id="O5" value="-1.0" spread="2.16"/>
                    <measurement group_id="O6" value="-0.3" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="2.40"/>
                    <measurement group_id="O2" value="-1.0" spread="1.49"/>
                    <measurement group_id="O3" value="-1.1" spread="1.52"/>
                    <measurement group_id="O4" value="-1.1" spread="1.57"/>
                    <measurement group_id="O5" value="-1.3" spread="2.55"/>
                    <measurement group_id="O6" value="-0.6" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="2.54"/>
                    <measurement group_id="O2" value="-1.8" spread="2.43"/>
                    <measurement group_id="O3" value="-0.5" spread="2.88"/>
                    <measurement group_id="O4" value="-1.9" spread="2.97"/>
                    <measurement group_id="O5" value="-1.2" spread="2.62"/>
                    <measurement group_id="O6" value="-1.3" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="2.71"/>
                    <measurement group_id="O2" value="-1.7" spread="2.54"/>
                    <measurement group_id="O3" value="-1.5" spread="2.00"/>
                    <measurement group_id="O4" value="-2.9" spread="3.08"/>
                    <measurement group_id="O5" value="-1.4" spread="2.61"/>
                    <measurement group_id="O6" value="-1.6" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="22"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="2.82"/>
                    <measurement group_id="O2" value="-2.3" spread="2.31"/>
                    <measurement group_id="O3" value="-2.1" spread="2.41"/>
                    <measurement group_id="O4" value="-3.1" spread="2.97"/>
                    <measurement group_id="O5" value="-2.0" spread="2.61"/>
                    <measurement group_id="O6" value="-1.9" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="2.90"/>
                    <measurement group_id="O2" value="-2.4" spread="2.56"/>
                    <measurement group_id="O3" value="-3.1" spread="2.12"/>
                    <measurement group_id="O4" value="-3.3" spread="2.93"/>
                    <measurement group_id="O5" value="-2.2" spread="2.59"/>
                    <measurement group_id="O6" value="-2.5" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="3.06"/>
                    <measurement group_id="O2" value="-2.5" spread="2.51"/>
                    <measurement group_id="O3" value="-3.3" spread="1.98"/>
                    <measurement group_id="O4" value="-3.3" spread="3.15"/>
                    <measurement group_id="O5" value="-2.8" spread="2.71"/>
                    <measurement group_id="O6" value="-2.9" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="2.77"/>
                    <measurement group_id="O2" value="-2.8" spread="2.47"/>
                    <measurement group_id="O3" value="-4.2" spread="2.05"/>
                    <measurement group_id="O4" value="-3.8" spread="3.19"/>
                    <measurement group_id="O5" value="-2.8" spread="2.61"/>
                    <measurement group_id="O6" value="-2.6" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="2.62"/>
                    <measurement group_id="O2" value="-2.6" spread="2.80"/>
                    <measurement group_id="O3" value="-3.6" spread="2.07"/>
                    <measurement group_id="O4" value="-3.7" spread="3.27"/>
                    <measurement group_id="O5" value="-3.1" spread="2.91"/>
                    <measurement group_id="O6" value="-2.7" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Patient's Global Joint and Skin Assessment-Visual Analog Scale (PGJS-VAS) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>Participant's perception of disease was assessed using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (excellent) and 100 (poor). The rating corresponded to the way in which the participant felt over the past week in terms of how they were affected by their: 1) psoriasis and arthritis (global, PGA); 2) arthritis only (PJA) and 3) psoriasis only (PSA). Rescaled VAS score was used. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). A negative change from baseline represents improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Patient's Global Joint and Skin Assessment-Visual Analog Scale (PGJS-VAS) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>Participant's perception of disease was assessed using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (excellent) and 100 (poor). The rating corresponded to the way in which the participant felt over the past week in terms of how they were affected by their: 1) psoriasis and arthritis (global, PGA); 2) arthritis only (PJA) and 3) psoriasis only (PSA). Rescaled VAS score was used. Rescaled VAS score (mm) = (100 mm) × (length at mark in mm/overall length of line in mm). A negative change from baseline represents improvement.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="26.88"/>
                    <measurement group_id="O2" value="-11.6" spread="22.31"/>
                    <measurement group_id="O3" value="-4.9" spread="12.42"/>
                    <measurement group_id="O4" value="-0.5" spread="12.41"/>
                    <measurement group_id="O5" value="-3.3" spread="14.50"/>
                    <measurement group_id="O6" value="-7.1" spread="17.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.0" spread="24.83"/>
                    <measurement group_id="O2" value="-18.8" spread="25.42"/>
                    <measurement group_id="O3" value="-13.2" spread="18.69"/>
                    <measurement group_id="O4" value="-7.1" spread="21.61"/>
                    <measurement group_id="O5" value="-11.6" spread="22.07"/>
                    <measurement group_id="O6" value="-6.2" spread="24.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.1" spread="26.95"/>
                    <measurement group_id="O2" value="-19.7" spread="27.56"/>
                    <measurement group_id="O3" value="-12.0" spread="26.52"/>
                    <measurement group_id="O4" value="-16.4" spread="25.36"/>
                    <measurement group_id="O5" value="-16.8" spread="26.21"/>
                    <measurement group_id="O6" value="-8.1" spread="24.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.1" spread="28.18"/>
                    <measurement group_id="O2" value="-25.3" spread="23.75"/>
                    <measurement group_id="O3" value="-18.0" spread="21.42"/>
                    <measurement group_id="O4" value="-17.6" spread="23.70"/>
                    <measurement group_id="O5" value="-14.4" spread="28.78"/>
                    <measurement group_id="O6" value="-9.5" spread="23.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.0" spread="24.78"/>
                    <measurement group_id="O2" value="-24.5" spread="25.43"/>
                    <measurement group_id="O3" value="-23.9" spread="21.10"/>
                    <measurement group_id="O4" value="-27.8" spread="21.23"/>
                    <measurement group_id="O5" value="-11.7" spread="23.36"/>
                    <measurement group_id="O6" value="-9.9" spread="23.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.1" spread="24.08"/>
                    <measurement group_id="O2" value="-30.5" spread="23.29"/>
                    <measurement group_id="O3" value="-27.3" spread="24.19"/>
                    <measurement group_id="O4" value="-22.6" spread="27.92"/>
                    <measurement group_id="O5" value="-36.3" spread="22.12"/>
                    <measurement group_id="O6" value="-26.3" spread="29.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.0" spread="24.53"/>
                    <measurement group_id="O2" value="-29.7" spread="28.36"/>
                    <measurement group_id="O3" value="-37.2" spread="22.80"/>
                    <measurement group_id="O4" value="-38.8" spread="25.73"/>
                    <measurement group_id="O5" value="-37.3" spread="25.35"/>
                    <measurement group_id="O6" value="-37.2" spread="24.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.1" spread="27.81"/>
                    <measurement group_id="O2" value="-29.6" spread="27.90"/>
                    <measurement group_id="O3" value="-42.0" spread="26.37"/>
                    <measurement group_id="O4" value="-33.7" spread="27.04"/>
                    <measurement group_id="O5" value="-36.0" spread="22.02"/>
                    <measurement group_id="O6" value="-39.4" spread="26.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.6" spread="28.52"/>
                    <measurement group_id="O2" value="-32.4" spread="28.81"/>
                    <measurement group_id="O3" value="-41.9" spread="19.08"/>
                    <measurement group_id="O4" value="-36.8" spread="30.62"/>
                    <measurement group_id="O5" value="-38.2" spread="26.65"/>
                    <measurement group_id="O6" value="-42.1" spread="27.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.3" spread="28.68"/>
                    <measurement group_id="O2" value="-32.7" spread="29.77"/>
                    <measurement group_id="O3" value="-35.6" spread="26.94"/>
                    <measurement group_id="O4" value="-33.9" spread="33.45"/>
                    <measurement group_id="O5" value="-39.1" spread="23.78"/>
                    <measurement group_id="O6" value="-38.3" spread="30.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The FACIT-F Scale is a patient completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue).</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The FACIT-F Scale is a patient completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue).</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="5.82"/>
                    <measurement group_id="O2" value="3.1" spread="5.85"/>
                    <measurement group_id="O3" value="0.9" spread="2.60"/>
                    <measurement group_id="O4" value="1.2" spread="6.45"/>
                    <measurement group_id="O5" value="0.9" spread="6.95"/>
                    <measurement group_id="O6" value="2.7" spread="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="7.47"/>
                    <measurement group_id="O2" value="5.7" spread="7.34"/>
                    <measurement group_id="O3" value="3.7" spread="5.40"/>
                    <measurement group_id="O4" value="3.7" spread="8.30"/>
                    <measurement group_id="O5" value="3.0" spread="10.76"/>
                    <measurement group_id="O6" value="2.5" spread="6.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="8.03"/>
                    <measurement group_id="O2" value="5.6" spread="8.44"/>
                    <measurement group_id="O3" value="3.6" spread="5.78"/>
                    <measurement group_id="O4" value="3.8" spread="6.24"/>
                    <measurement group_id="O5" value="3.2" spread="10.31"/>
                    <measurement group_id="O6" value="3.7" spread="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="10.17"/>
                    <measurement group_id="O2" value="7.3" spread="7.96"/>
                    <measurement group_id="O3" value="3.2" spread="4.10"/>
                    <measurement group_id="O4" value="6.1" spread="7.85"/>
                    <measurement group_id="O5" value="5.5" spread="9.55"/>
                    <measurement group_id="O6" value="3.8" spread="9.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="7.74"/>
                    <measurement group_id="O2" value="7.1" spread="9.41"/>
                    <measurement group_id="O3" value="4.4" spread="5.40"/>
                    <measurement group_id="O4" value="6.0" spread="6.89"/>
                    <measurement group_id="O5" value="4.7" spread="8.10"/>
                    <measurement group_id="O6" value="4.7" spread="8.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="8.69"/>
                    <measurement group_id="O2" value="9.5" spread="8.20"/>
                    <measurement group_id="O3" value="7.2" spread="5.86"/>
                    <measurement group_id="O4" value="7.0" spread="7.94"/>
                    <measurement group_id="O5" value="8.9" spread="8.11"/>
                    <measurement group_id="O6" value="9.3" spread="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="9.67"/>
                    <measurement group_id="O2" value="9.5" spread="8.22"/>
                    <measurement group_id="O3" value="7.2" spread="7.73"/>
                    <measurement group_id="O4" value="12.3" spread="11.48"/>
                    <measurement group_id="O5" value="9.8" spread="10.02"/>
                    <measurement group_id="O6" value="11.7" spread="10.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="9.51"/>
                    <measurement group_id="O2" value="8.4" spread="8.25"/>
                    <measurement group_id="O3" value="7.3" spread="5.54"/>
                    <measurement group_id="O4" value="10.6" spread="11.36"/>
                    <measurement group_id="O5" value="9.6" spread="6.48"/>
                    <measurement group_id="O6" value="11.3" spread="11.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="9.00"/>
                    <measurement group_id="O2" value="10.0" spread="9.52"/>
                    <measurement group_id="O3" value="7.9" spread="5.07"/>
                    <measurement group_id="O4" value="13.1" spread="11.10"/>
                    <measurement group_id="O5" value="7.7" spread="7.89"/>
                    <measurement group_id="O6" value="11.8" spread="11.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="8.54"/>
                    <measurement group_id="O2" value="10.4" spread="9.86"/>
                    <measurement group_id="O3" value="9.4" spread="9.01"/>
                    <measurement group_id="O4" value="12.3" spread="12.74"/>
                    <measurement group_id="O5" value="10.5" spread="8.91"/>
                    <measurement group_id="O6" value="10.5" spread="10.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Short-Form-36 Health Survey (SF-36) Version 2, Acute at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The SF-36 version 2 (Acute version) is a 36-item generic health status measure. It measures 8 general health concepts or domains: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). These 8 domains can also be summarized as physical and mental component scores. The summary component scores, Physical Component Summary (PCS) and Mental Component Summary (MCS), are based on a normalized sum of the 8 scale scores PF, RP, BP, GH, VT, SF, RE, and MH. All domains and summary components are scored such that a higher score indicates a higher functioning or health level. The minimum and maximum scores of the PCS Score are 22 and 59 respectively. The minimum and maximum scores of the MCS Score are 11 and 62 respectively.</description>
        <time_frame>Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Short-Form-36 Health Survey (SF-36) Version 2, Acute at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The SF-36 version 2 (Acute version) is a 36-item generic health status measure. It measures 8 general health concepts or domains: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). These 8 domains can also be summarized as physical and mental component scores. The summary component scores, Physical Component Summary (PCS) and Mental Component Summary (MCS), are based on a normalized sum of the 8 scale scores PF, RP, BP, GH, VT, SF, RE, and MH. All domains and summary components are scored such that a higher score indicates a higher functioning or health level. The minimum and maximum scores of the PCS Score are 22 and 59 respectively. The minimum and maximum scores of the MCS Score are 11 and 62 respectively.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (Physical Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" spread="7.092"/>
                    <measurement group_id="O2" value="4.24" spread="7.602"/>
                    <measurement group_id="O3" value="2.59" spread="5.263"/>
                    <measurement group_id="O4" value="1.01" spread="3.944"/>
                    <measurement group_id="O5" value="1.66" spread="5.845"/>
                    <measurement group_id="O6" value="2.64" spread="6.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Physical Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="8.297"/>
                    <measurement group_id="O2" value="5.97" spread="8.261"/>
                    <measurement group_id="O3" value="5.53" spread="9.387"/>
                    <measurement group_id="O4" value="2.47" spread="3.675"/>
                    <measurement group_id="O5" value="2.57" spread="6.457"/>
                    <measurement group_id="O6" value="3.04" spread="5.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Physical Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="8.403"/>
                    <measurement group_id="O2" value="4.86" spread="9.010"/>
                    <measurement group_id="O3" value="7.28" spread="7.232"/>
                    <measurement group_id="O4" value="2.29" spread="4.283"/>
                    <measurement group_id="O5" value="2.22" spread="6.205"/>
                    <measurement group_id="O6" value="3.07" spread="7.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Physical Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.40" spread="8.239"/>
                    <measurement group_id="O2" value="7.27" spread="8.627"/>
                    <measurement group_id="O3" value="6.97" spread="7.223"/>
                    <measurement group_id="O4" value="5.07" spread="4.763"/>
                    <measurement group_id="O5" value="2.36" spread="6.842"/>
                    <measurement group_id="O6" value="1.79" spread="6.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (Physical Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.75" spread="8.579"/>
                    <measurement group_id="O2" value="8.84" spread="8.231"/>
                    <measurement group_id="O3" value="9.53" spread="8.434"/>
                    <measurement group_id="O4" value="2.03" spread="6.756"/>
                    <measurement group_id="O5" value="6.14" spread="7.513"/>
                    <measurement group_id="O6" value="6.25" spread="8.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (Physical Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.16" spread="8.691"/>
                    <measurement group_id="O2" value="9.06" spread="9.597"/>
                    <measurement group_id="O3" value="9.42" spread="7.751"/>
                    <measurement group_id="O4" value="7.84" spread="7.127"/>
                    <measurement group_id="O5" value="5.67" spread="7.933"/>
                    <measurement group_id="O6" value="9.22" spread="8.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (Physical Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.58" spread="9.510"/>
                    <measurement group_id="O2" value="7.75" spread="9.223"/>
                    <measurement group_id="O3" value="9.08" spread="9.789"/>
                    <measurement group_id="O4" value="6.44" spread="7.245"/>
                    <measurement group_id="O5" value="5.96" spread="6.738"/>
                    <measurement group_id="O6" value="9.41" spread="8.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (Physical Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" spread="9.541"/>
                    <measurement group_id="O2" value="9.23" spread="9.477"/>
                    <measurement group_id="O3" value="8.44" spread="9.527"/>
                    <measurement group_id="O4" value="7.13" spread="6.759"/>
                    <measurement group_id="O5" value="6.00" spread="6.937"/>
                    <measurement group_id="O6" value="9.18" spread="8.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (Physical Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.52" spread="9.818"/>
                    <measurement group_id="O2" value="9.98" spread="9.150"/>
                    <measurement group_id="O3" value="9.55" spread="9.536"/>
                    <measurement group_id="O4" value="6.64" spread="7.925"/>
                    <measurement group_id="O5" value="7.21" spread="8.130"/>
                    <measurement group_id="O6" value="9.84" spread="9.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Mental Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="10.643"/>
                    <measurement group_id="O2" value="3.79" spread="9.139"/>
                    <measurement group_id="O3" value="1.24" spread="5.426"/>
                    <measurement group_id="O4" value="3.99" spread="10.723"/>
                    <measurement group_id="O5" value="0.45" spread="7.539"/>
                    <measurement group_id="O6" value="-1.09" spread="9.805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Mental Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="9.810"/>
                    <measurement group_id="O2" value="2.84" spread="10.894"/>
                    <measurement group_id="O3" value="-2.05" spread="10.553"/>
                    <measurement group_id="O4" value="6.91" spread="10.450"/>
                    <measurement group_id="O5" value="0.29" spread="10.253"/>
                    <measurement group_id="O6" value="0.75" spread="8.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Mental Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="9.860"/>
                    <measurement group_id="O2" value="4.99" spread="10.307"/>
                    <measurement group_id="O3" value="0.78" spread="8.488"/>
                    <measurement group_id="O4" value="5.15" spread="13.189"/>
                    <measurement group_id="O5" value="1.37" spread="11.261"/>
                    <measurement group_id="O6" value="1.50" spread="9.640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (Mental Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="10.848"/>
                    <measurement group_id="O2" value="2.12" spread="11.369"/>
                    <measurement group_id="O3" value="1.01" spread="6.995"/>
                    <measurement group_id="O4" value="4.78" spread="10.930"/>
                    <measurement group_id="O5" value="2.83" spread="8.459"/>
                    <measurement group_id="O6" value="3.03" spread="9.824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (Mental Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="10.131"/>
                    <measurement group_id="O2" value="3.59" spread="10.763"/>
                    <measurement group_id="O3" value="2.76" spread="8.595"/>
                    <measurement group_id="O4" value="6.58" spread="10.796"/>
                    <measurement group_id="O5" value="4.99" spread="8.782"/>
                    <measurement group_id="O6" value="6.72" spread="8.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (Mental Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" spread="11.295"/>
                    <measurement group_id="O2" value="3.64" spread="11.004"/>
                    <measurement group_id="O3" value="3.54" spread="7.290"/>
                    <measurement group_id="O4" value="8.95" spread="12.914"/>
                    <measurement group_id="O5" value="6.08" spread="7.764"/>
                    <measurement group_id="O6" value="6.57" spread="9.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (Mental Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" spread="9.044"/>
                    <measurement group_id="O2" value="5.41" spread="11.649"/>
                    <measurement group_id="O3" value="4.74" spread="9.301"/>
                    <measurement group_id="O4" value="8.53" spread="14.210"/>
                    <measurement group_id="O5" value="6.58" spread="7.419"/>
                    <measurement group_id="O6" value="5.47" spread="10.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (Mental Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.14" spread="9.745"/>
                    <measurement group_id="O2" value="4.43" spread="13.601"/>
                    <measurement group_id="O3" value="4.29" spread="10.641"/>
                    <measurement group_id="O4" value="7.70" spread="13.606"/>
                    <measurement group_id="O5" value="6.33" spread="7.785"/>
                    <measurement group_id="O6" value="4.98" spread="10.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (Mental Component Summary Score)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="10.023"/>
                    <measurement group_id="O2" value="4.33" spread="13.303"/>
                    <measurement group_id="O3" value="3.63" spread="10.656"/>
                    <measurement group_id="O4" value="8.69" spread="16.192"/>
                    <measurement group_id="O5" value="5.68" spread="8.783"/>
                    <measurement group_id="O6" value="4.35" spread="10.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Minimal Disease Activity (MDA) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>A psoriatic arthritis participant was defined as having MDA response when 5 of the 7 following criteria were met: 1) tender joint count ≤1; 2) swollen joint count ≤1; 3) Psoriasis Area and Severity Index (quantifying the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area affected) score ≤1 or Body Surface Area (assessment of body surface area involved in psoriasis) ≤3%; 4) Patient's Assessment of Arthritis Pain (assessment of the patient's level of pain using a horizontal 100 mm visual analog scale) ≤15 mm; 5) Patient's Global Arthritis Assessment (patient's overall assessment of how the arthritis was doing by a 100 mm visual analog scale) ≤20 mm; 6) Health Assessment Questionnaire - Disability Index (assessment of the degree of difficulty a patient experienced) score ≤0.5; 7) tender entheseal points (assessment of tenderness using Leed's Enthesitis Index) ≤1.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Minimal Disease Activity (MDA) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>A psoriatic arthritis participant was defined as having MDA response when 5 of the 7 following criteria were met: 1) tender joint count ≤1; 2) swollen joint count ≤1; 3) Psoriasis Area and Severity Index (quantifying the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area affected) score ≤1 or Body Surface Area (assessment of body surface area involved in psoriasis) ≤3%; 4) Patient's Assessment of Arthritis Pain (assessment of the patient's level of pain using a horizontal 100 mm visual analog scale) ≤15 mm; 5) Patient's Global Arthritis Assessment (patient's overall assessment of how the arthritis was doing by a 100 mm visual analog scale) ≤20 mm; 6) Health Assessment Questionnaire - Disability Index (assessment of the degree of difficulty a patient experienced) score ≤0.5; 7) tender entheseal points (assessment of tenderness using Leed's Enthesitis Index) ≤1.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33" lower_limit="1.34" upper_limit="15.33"/>
                    <measurement group_id="O2" value="8.33" lower_limit="1.34" upper_limit="15.33"/>
                    <measurement group_id="O3" value="6.25" lower_limit="0.00" upper_limit="18.11"/>
                    <measurement group_id="O4" value="3.13" lower_limit="0.00" upper_limit="11.65"/>
                    <measurement group_id="O5" value="1.43" lower_limit="0.00" upper_limit="5.36"/>
                    <measurement group_id="O6" value="3.03" lower_limit="0.00" upper_limit="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.67" lower_limit="15.48" upper_limit="37.86"/>
                    <measurement group_id="O2" value="21.67" lower_limit="11.24" upper_limit="32.09"/>
                    <measurement group_id="O3" value="18.75" lower_limit="0.00" upper_limit="37.87"/>
                    <measurement group_id="O4" value="6.67" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O5" value="5.88" lower_limit="0.00" upper_limit="13.79"/>
                    <measurement group_id="O6" value="12.12" lower_limit="0.99" upper_limit="23.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.67" lower_limit="19.90" upper_limit="43.44"/>
                    <measurement group_id="O2" value="25.00" lower_limit="14.04" upper_limit="35.96"/>
                    <measurement group_id="O3" value="18.75" lower_limit="0.00" upper_limit="37.87"/>
                    <measurement group_id="O4" value="20.00" lower_limit="0.00" upper_limit="40.24"/>
                    <measurement group_id="O5" value="5.88" lower_limit="0.00" upper_limit="13.79"/>
                    <measurement group_id="O6" value="12.12" lower_limit="0.99" upper_limit="23.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.59" lower_limit="23.38" upper_limit="47.81"/>
                    <measurement group_id="O2" value="35.00" lower_limit="22.93" upper_limit="47.07"/>
                    <measurement group_id="O3" value="18.75" lower_limit="0.00" upper_limit="37.87"/>
                    <measurement group_id="O4" value="20.00" lower_limit="0.00" upper_limit="40.24"/>
                    <measurement group_id="O5" value="2.94" lower_limit="0.00" upper_limit="8.62"/>
                    <measurement group_id="O6" value="3.03" lower_limit="0.00" upper_limit="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.00" lower_limit="32.41" upper_limit="57.59"/>
                    <measurement group_id="O2" value="38.33" lower_limit="26.03" upper_limit="50.64"/>
                    <measurement group_id="O3" value="25.00" lower_limit="3.78" upper_limit="46.22"/>
                    <measurement group_id="O4" value="26.67" lower_limit="4.29" upper_limit="49.05"/>
                    <measurement group_id="O5" value="29.41" lower_limit="14.10" upper_limit="44.73"/>
                    <measurement group_id="O6" value="24.24" lower_limit="9.62" upper_limit="38.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.33" lower_limit="30.79" upper_limit="55.87"/>
                    <measurement group_id="O2" value="46.67" lower_limit="34.04" upper_limit="59.29"/>
                    <measurement group_id="O3" value="31.25" lower_limit="8.54" upper_limit="53.96"/>
                    <measurement group_id="O4" value="33.33" lower_limit="9.48" upper_limit="57.19"/>
                    <measurement group_id="O5" value="32.35" lower_limit="16.63" upper_limit="48.08"/>
                    <measurement group_id="O6" value="45.45" lower_limit="28.47" upper_limit="62.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.33" lower_limit="30.79" upper_limit="55.87"/>
                    <measurement group_id="O2" value="43.33" lower_limit="30.79" upper_limit="55.87"/>
                    <measurement group_id="O3" value="50.00" lower_limit="25.50" upper_limit="74.50"/>
                    <measurement group_id="O4" value="60.00" lower_limit="35.21" upper_limit="84.79"/>
                    <measurement group_id="O5" value="29.41" lower_limit="14.10" upper_limit="44.73"/>
                    <measurement group_id="O6" value="57.58" lower_limit="40.71" upper_limit="74.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.33" lower_limit="40.71" upper_limit="65.96"/>
                    <measurement group_id="O2" value="50.00" lower_limit="37.35" upper_limit="62.65"/>
                    <measurement group_id="O3" value="31.25" lower_limit="8.54" upper_limit="53.96"/>
                    <measurement group_id="O4" value="46.67" lower_limit="21.42" upper_limit="71.91"/>
                    <measurement group_id="O5" value="32.35" lower_limit="16.63" upper_limit="48.08"/>
                    <measurement group_id="O6" value="51.52" lower_limit="34.46" upper_limit="68.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.67" lower_limit="34.04" upper_limit="59.29"/>
                    <measurement group_id="O2" value="48.33" lower_limit="35.69" upper_limit="60.98"/>
                    <measurement group_id="O3" value="31.25" lower_limit="8.54" upper_limit="53.96"/>
                    <measurement group_id="O4" value="40.00" lower_limit="15.21" upper_limit="64.79"/>
                    <measurement group_id="O5" value="41.18" lower_limit="24.63" upper_limit="57.72"/>
                    <measurement group_id="O6" value="45.45" lower_limit="28.47" upper_limit="62.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Very Low Disease Activity (VLDA) Response at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>A participant was in VLDA when all the 7 following criteria were met: 1) tender joint count ≤1; 2) swollen joint count ≤1; 3) Psoriasis Area and Severity Index (quantifying the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area affected) score ≤1 or Body Surface Area (assessment of body surface area involved in psoriasis) ≤3%; 4) Patient's Assessment of Arthritis Pain (assessment of the patient's level of pain using a horizontal 100 mm visual analog scale) ≤15 mm; 5) Patient's Global Arthritis Assessment (patient's overall assessment of how the arthritis was doing by a 100 mm visual analog scale) ≤20 mm; 6) Health Assessment Questionnaire - Disability Index (assessment of the degree of difficulty a patient experienced) score ≤0.5; 7) tender entheseal points (assessment of tenderness using Leed's Enthesitis Index) ≤1.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Very Low Disease Activity (VLDA) Response at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>A participant was in VLDA when all the 7 following criteria were met: 1) tender joint count ≤1; 2) swollen joint count ≤1; 3) Psoriasis Area and Severity Index (quantifying the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area affected) score ≤1 or Body Surface Area (assessment of body surface area involved in psoriasis) ≤3%; 4) Patient's Assessment of Arthritis Pain (assessment of the patient's level of pain using a horizontal 100 mm visual analog scale) ≤15 mm; 5) Patient's Global Arthritis Assessment (patient's overall assessment of how the arthritis was doing by a 100 mm visual analog scale) ≤20 mm; 6) Health Assessment Questionnaire - Disability Index (assessment of the degree of difficulty a patient experienced) score ≤0.5; 7) tender entheseal points (assessment of tenderness using Leed's Enthesitis Index) ≤1.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified visit.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" lower_limit="0.00" upper_limit="3.08"/>
                    <measurement group_id="O2" value="0.82" lower_limit="0.00" upper_limit="3.08"/>
                    <measurement group_id="O3" value="2.94" lower_limit="0.00" upper_limit="10.97"/>
                    <measurement group_id="O4" value="3.13" lower_limit="0.00" upper_limit="11.65"/>
                    <measurement group_id="O5" value="1.43" lower_limit="0.00" upper_limit="5.36"/>
                    <measurement group_id="O6" value="1.47" lower_limit="0.00" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" lower_limit="0.00" upper_limit="4.91"/>
                    <measurement group_id="O2" value="1.67" lower_limit="0.00" upper_limit="4.91"/>
                    <measurement group_id="O3" value="2.94" lower_limit="0.00" upper_limit="10.97"/>
                    <measurement group_id="O4" value="3.13" lower_limit="0.00" upper_limit="11.65"/>
                    <measurement group_id="O5" value="1.43" lower_limit="0.00" upper_limit="5.36"/>
                    <measurement group_id="O6" value="1.47" lower_limit="0.00" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" lower_limit="0.00" upper_limit="3.08"/>
                    <measurement group_id="O2" value="3.33" lower_limit="0.00" upper_limit="7.88"/>
                    <measurement group_id="O3" value="2.94" lower_limit="0.00" upper_limit="10.97"/>
                    <measurement group_id="O4" value="3.13" lower_limit="0.00" upper_limit="11.65"/>
                    <measurement group_id="O5" value="1.43" lower_limit="0.00" upper_limit="5.36"/>
                    <measurement group_id="O6" value="1.47" lower_limit="0.00" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" lower_limit="0.00" upper_limit="8.01"/>
                    <measurement group_id="O2" value="5.00" lower_limit="0.00" upper_limit="10.51"/>
                    <measurement group_id="O3" value="6.25" lower_limit="0.00" upper_limit="18.11"/>
                    <measurement group_id="O4" value="3.13" lower_limit="0.00" upper_limit="11.65"/>
                    <measurement group_id="O5" value="1.43" lower_limit="0.00" upper_limit="5.36"/>
                    <measurement group_id="O6" value="1.47" lower_limit="0.00" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" lower_limit="0.35" upper_limit="12.98"/>
                    <measurement group_id="O2" value="11.67" lower_limit="3.54" upper_limit="19.79"/>
                    <measurement group_id="O3" value="12.50" lower_limit="0.00" upper_limit="28.70"/>
                    <measurement group_id="O4" value="13.33" lower_limit="0.00" upper_limit="30.54"/>
                    <measurement group_id="O5" value="2.94" lower_limit="0.00" upper_limit="8.62"/>
                    <measurement group_id="O6" value="1.47" lower_limit="0.00" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" lower_limit="2.41" upper_limit="17.59"/>
                    <measurement group_id="O2" value="10.00" lower_limit="2.41" upper_limit="17.59"/>
                    <measurement group_id="O3" value="12.50" lower_limit="0.00" upper_limit="28.70"/>
                    <measurement group_id="O4" value="6.67" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O5" value="8.82" lower_limit="0.00" upper_limit="18.36"/>
                    <measurement group_id="O6" value="6.06" lower_limit="0.00" upper_limit="14.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.00" lower_limit="5.97" upper_limit="24.03"/>
                    <measurement group_id="O2" value="15.00" lower_limit="5.97" upper_limit="24.03"/>
                    <measurement group_id="O3" value="12.50" lower_limit="0.00" upper_limit="28.70"/>
                    <measurement group_id="O4" value="6.67" lower_limit="0.00" upper_limit="19.29"/>
                    <measurement group_id="O5" value="5.88" lower_limit="0.00" upper_limit="13.79"/>
                    <measurement group_id="O6" value="12.12" lower_limit="0.99" upper_limit="23.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.00" lower_limit="5.97" upper_limit="24.03"/>
                    <measurement group_id="O2" value="16.67" lower_limit="7.24" upper_limit="26.10"/>
                    <measurement group_id="O3" value="18.75" lower_limit="0.00" upper_limit="37.87"/>
                    <measurement group_id="O4" value="20.00" lower_limit="0.00" upper_limit="40.24"/>
                    <measurement group_id="O5" value="14.71" lower_limit="2.80" upper_limit="26.61"/>
                    <measurement group_id="O6" value="15.15" lower_limit="2.92" upper_limit="27.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00" lower_limit="9.88" upper_limit="30.12"/>
                    <measurement group_id="O2" value="16.67" lower_limit="7.24" upper_limit="26.10"/>
                    <measurement group_id="O3" value="25.00" lower_limit="3.78" upper_limit="46.22"/>
                    <measurement group_id="O4" value="20.00" lower_limit="0.00" upper_limit="40.24"/>
                    <measurement group_id="O5" value="11.76" lower_limit="0.93" upper_limit="22.59"/>
                    <measurement group_id="O6" value="18.18" lower_limit="5.02" upper_limit="31.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Disease Activity Index for Reactive Arthritis/PsA (DAREA/DAPSA) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>DAREA/DAPSA is a composite instrument to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count + swollen joint count (using SJC66/ TJC68 assessments), Patient's Global Assessment of Arthritis (PtGA in cm), Patient's Assessment of Arthritis Pain (PAIN in cm) and C-reactive protein (CRP) (in mg/dL). Since DAREA reflects domains found important in PsA, it has been proposed to serve as a Disease Activity Index for Psoriatic Arthritis (DAPSA). DAREA/DAPSA was calculated as follows: DAREA/DAPSA= SJC66 + TJC68 + PtGA + PAIN + CRP. A negative change from baseline represents improvement.</description>
        <time_frame>Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; included all the participants in the evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline DAREA/DAPSA. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints with baseline DAREA/DAPSA.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Disease Activity Index for Reactive Arthritis/PsA (DAREA/DAPSA) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>DAREA/DAPSA is a composite instrument to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count + swollen joint count (using SJC66/ TJC68 assessments), Patient's Global Assessment of Arthritis (PtGA in cm), Patient's Assessment of Arthritis Pain (PAIN in cm) and C-reactive protein (CRP) (in mg/dL). Since DAREA reflects domains found important in PsA, it has been proposed to serve as a Disease Activity Index for Psoriatic Arthritis (DAPSA). DAREA/DAPSA was calculated as follows: DAREA/DAPSA= SJC66 + TJC68 + PtGA + PAIN + CRP. A negative change from baseline represents improvement.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; included all the participants in the evaluable population (participants who were randomized to the study and received at least one dose of the randomized study treatment) with baseline DAREA/DAPSA. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints with baseline DAREA/DAPSA.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.05" spread="11.826"/>
                    <measurement group_id="O2" value="-13.99" spread="10.166"/>
                    <measurement group_id="O3" value="-14.15" spread="14.294"/>
                    <measurement group_id="O4" value="-9.81" spread="13.841"/>
                    <measurement group_id="O5" value="-7.11" spread="8.738"/>
                    <measurement group_id="O6" value="-9.08" spread="12.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.36" spread="11.211"/>
                    <measurement group_id="O2" value="-17.55" spread="11.664"/>
                    <measurement group_id="O3" value="-19.19" spread="11.720"/>
                    <measurement group_id="O4" value="-14.33" spread="15.143"/>
                    <measurement group_id="O5" value="-12.46" spread="12.905"/>
                    <measurement group_id="O6" value="-10.98" spread="15.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.93" spread="12.582"/>
                    <measurement group_id="O2" value="-20.91" spread="11.985"/>
                    <measurement group_id="O3" value="-24.91" spread="15.556"/>
                    <measurement group_id="O4" value="-17.77" spread="18.471"/>
                    <measurement group_id="O5" value="-14.68" spread="12.943"/>
                    <measurement group_id="O6" value="-13.04" spread="15.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.15" spread="12.582"/>
                    <measurement group_id="O2" value="-23.55" spread="12.040"/>
                    <measurement group_id="O3" value="-26.65" spread="16.982"/>
                    <measurement group_id="O4" value="-25.89" spread="18.513"/>
                    <measurement group_id="O5" value="-15.83" spread="12.918"/>
                    <measurement group_id="O6" value="-14.45" spread="15.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.75" spread="13.625"/>
                    <measurement group_id="O2" value="-25.24" spread="12.152"/>
                    <measurement group_id="O3" value="-30.63" spread="17.150"/>
                    <measurement group_id="O4" value="-27.01" spread="22.334"/>
                    <measurement group_id="O5" value="-23.53" spread="13.606"/>
                    <measurement group_id="O6" value="-23.63" spread="13.640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.13" spread="12.807"/>
                    <measurement group_id="O2" value="-25.38" spread="13.129"/>
                    <measurement group_id="O3" value="-32.63" spread="18.437"/>
                    <measurement group_id="O4" value="-31.41" spread="22.145"/>
                    <measurement group_id="O5" value="-23.54" spread="12.375"/>
                    <measurement group_id="O6" value="-27.55" spread="14.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.21" spread="14.456"/>
                    <measurement group_id="O2" value="-25.84" spread="13.170"/>
                    <measurement group_id="O3" value="-34.98" spread="19.857"/>
                    <measurement group_id="O4" value="-31.53" spread="24.046"/>
                    <measurement group_id="O5" value="-25.57" spread="11.445"/>
                    <measurement group_id="O6" value="-28.22" spread="15.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.39" spread="14.445"/>
                    <measurement group_id="O2" value="-27.54" spread="12.744"/>
                    <measurement group_id="O3" value="-36.61" spread="14.597"/>
                    <measurement group_id="O4" value="-30.22" spread="27.532"/>
                    <measurement group_id="O5" value="-26.43" spread="10.880"/>
                    <measurement group_id="O6" value="-29.59" spread="15.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.56" spread="15.578"/>
                    <measurement group_id="O2" value="-27.40" spread="13.429"/>
                    <measurement group_id="O3" value="-37.81" spread="14.251"/>
                    <measurement group_id="O4" value="-30.32" spread="22.795"/>
                    <measurement group_id="O5" value="-26.45" spread="11.114"/>
                    <measurement group_id="O6" value="-28.95" spread="17.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving the Psoriatic Arthritis Response Criteria (PsARC) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>The PsARC response was defined as improvement in two of the following 4 criteria, one of which must be joint pain or swelling, without worsening in any measure: (1) ≥20% improvement in Physician's Global Assessment of Arthritis (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity); (2) ≥20% improvement in Patient's Global Assessment of Arthritis (the patient's overall assessment of how the arthritis was doing by a visual analog scale); (3) ≥30% improvement in tender joint count (68); and (4) ≥30% improvement in swollen joint count.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving the Psoriatic Arthritis Response Criteria (PsARC) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>The PsARC response was defined as improvement in two of the following 4 criteria, one of which must be joint pain or swelling, without worsening in any measure: (1) ≥20% improvement in Physician's Global Assessment of Arthritis (a horizontal visual analog scale measure of the physician's assessment of the patient's current disease activity); (2) ≥20% improvement in Patient's Global Assessment of Arthritis (the patient's overall assessment of how the arthritis was doing by a visual analog scale); (3) ≥30% improvement in tender joint count (68); and (4) ≥30% improvement in swollen joint count.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00" lower_limit="37.35" upper_limit="62.65"/>
                    <measurement group_id="O2" value="55.00" lower_limit="42.41" upper_limit="67.59"/>
                    <measurement group_id="O3" value="50.00" lower_limit="25.50" upper_limit="74.50"/>
                    <measurement group_id="O4" value="40.00" lower_limit="15.21" upper_limit="64.79"/>
                    <measurement group_id="O5" value="26.47" lower_limit="11.64" upper_limit="41.30"/>
                    <measurement group_id="O6" value="21.21" lower_limit="7.26" upper_limit="35.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" lower_limit="54.74" upper_limit="78.59"/>
                    <measurement group_id="O2" value="60.00" lower_limit="47.60" upper_limit="72.40"/>
                    <measurement group_id="O3" value="56.25" lower_limit="31.94" upper_limit="80.56"/>
                    <measurement group_id="O4" value="40.00" lower_limit="15.21" upper_limit="64.79"/>
                    <measurement group_id="O5" value="38.24" lower_limit="21.90" upper_limit="54.57"/>
                    <measurement group_id="O6" value="45.45" lower_limit="28.47" upper_limit="62.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" lower_limit="54.74" upper_limit="78.59"/>
                    <measurement group_id="O2" value="75.00" lower_limit="64.04" upper_limit="85.96"/>
                    <measurement group_id="O3" value="62.50" lower_limit="38.78" upper_limit="86.22"/>
                    <measurement group_id="O4" value="60.00" lower_limit="35.21" upper_limit="84.79"/>
                    <measurement group_id="O5" value="52.94" lower_limit="36.16" upper_limit="69.72"/>
                    <measurement group_id="O6" value="45.45" lower_limit="28.47" upper_limit="62.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.05" lower_limit="73.48" upper_limit="92.62"/>
                    <measurement group_id="O2" value="75.00" lower_limit="64.04" upper_limit="85.96"/>
                    <measurement group_id="O3" value="62.50" lower_limit="38.78" upper_limit="86.22"/>
                    <measurement group_id="O4" value="66.67" lower_limit="42.81" upper_limit="90.52"/>
                    <measurement group_id="O5" value="50.00" lower_limit="33.19" upper_limit="66.81"/>
                    <measurement group_id="O6" value="48.48" lower_limit="31.43" upper_limit="65.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.33" lower_limit="67.91" upper_limit="88.76"/>
                    <measurement group_id="O2" value="81.67" lower_limit="71.88" upper_limit="91.46"/>
                    <measurement group_id="O3" value="56.25" lower_limit="31.94" upper_limit="80.56"/>
                    <measurement group_id="O4" value="60.00" lower_limit="35.21" upper_limit="84.79"/>
                    <measurement group_id="O5" value="70.59" lower_limit="55.27" upper_limit="85.90"/>
                    <measurement group_id="O6" value="72.73" lower_limit="57.53" upper_limit="87.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.67" lower_limit="71.88" upper_limit="91.46"/>
                    <measurement group_id="O2" value="80.00" lower_limit="69.88" upper_limit="90.12"/>
                    <measurement group_id="O3" value="68.75" lower_limit="46.04" upper_limit="91.46"/>
                    <measurement group_id="O4" value="73.33" lower_limit="50.95" upper_limit="95.71"/>
                    <measurement group_id="O5" value="73.53" lower_limit="58.70" upper_limit="88.36"/>
                    <measurement group_id="O6" value="75.76" lower_limit="61.14" upper_limit="90.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" lower_limit="54.74" upper_limit="78.59"/>
                    <measurement group_id="O2" value="75.00" lower_limit="64.04" upper_limit="85.96"/>
                    <measurement group_id="O3" value="68.75" lower_limit="46.04" upper_limit="91.46"/>
                    <measurement group_id="O4" value="80.00" lower_limit="59.76" upper_limit="100.00"/>
                    <measurement group_id="O5" value="67.65" lower_limit="51.92" upper_limit="83.37"/>
                    <measurement group_id="O6" value="84.85" lower_limit="72.62" upper_limit="97.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" lower_limit="54.74" upper_limit="78.59"/>
                    <measurement group_id="O2" value="78.33" lower_limit="67.91" upper_limit="88.76"/>
                    <measurement group_id="O3" value="56.25" lower_limit="31.94" upper_limit="80.56"/>
                    <measurement group_id="O4" value="73.33" lower_limit="50.95" upper_limit="95.71"/>
                    <measurement group_id="O5" value="58.82" lower_limit="42.28" upper_limit="75.37"/>
                    <measurement group_id="O6" value="75.76" lower_limit="61.14" upper_limit="90.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.33" lower_limit="45.86" upper_limit="70.81"/>
                    <measurement group_id="O2" value="70.00" lower_limit="58.40" upper_limit="81.60"/>
                    <measurement group_id="O3" value="56.25" lower_limit="31.94" upper_limit="80.56"/>
                    <measurement group_id="O4" value="66.67" lower_limit="42.81" upper_limit="90.52"/>
                    <measurement group_id="O5" value="64.71" lower_limit="48.64" upper_limit="80.77"/>
                    <measurement group_id="O6" value="66.67" lower_limit="50.58" upper_limit="82.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
        <description>PASDAS is a composite psoriatic arthritis disease activity score that includes the following components: patient's global joint and skin assessment (visual analog scale in mm), physician's global psoriatic arthritis assessment (visual analog scale in mm), swollen (66 joints) and tender joint counts (68 joints), Leeds Enthesitis Index score, tender dactylitic digit score, physical component summary score (PCS) of Short Form 36 Health Survey and C-reactive protein (mg/L). Any missing component would result in PASDAS as missing. A higher PASDAS score indicates a higher disease activity.</description>
        <time_frame>Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</time_frame>
        <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at Weeks 4, 8, 12, 16, 20, 28, 36, 44 and 52</title>
          <description>PASDAS is a composite psoriatic arthritis disease activity score that includes the following components: patient's global joint and skin assessment (visual analog scale in mm), physician's global psoriatic arthritis assessment (visual analog scale in mm), swollen (66 joints) and tender joint counts (68 joints), Leeds Enthesitis Index score, tender dactylitic digit score, physical component summary score (PCS) of Short Form 36 Health Survey and C-reactive protein (mg/L). Any missing component would result in PASDAS as missing. A higher PASDAS score indicates a higher disease activity.</description>
          <population>&quot;Overall Number of Participants Analyzed&quot; indicated the evaluable population and included all participants who were randomized to the study and received at least one dose of the randomized study treatment. &quot;Number Analyzed&quot; included participants available in the evaluable population at each specified treatment timepoints.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="1.119"/>
                    <measurement group_id="O2" value="-1.31" spread="1.090"/>
                    <measurement group_id="O3" value="-0.94" spread="0.957"/>
                    <measurement group_id="O4" value="-0.65" spread="0.653"/>
                    <measurement group_id="O5" value="-0.56" spread="0.655"/>
                    <measurement group_id="O6" value="-0.54" spread="0.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.79" spread="1.295"/>
                    <measurement group_id="O2" value="-1.65" spread="1.262"/>
                    <measurement group_id="O3" value="-1.37" spread="1.127"/>
                    <measurement group_id="O4" value="-1.14" spread="1.122"/>
                    <measurement group_id="O5" value="-1.02" spread="0.988"/>
                    <measurement group_id="O6" value="-0.67" spread="1.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.10" spread="1.380"/>
                    <measurement group_id="O2" value="-1.93" spread="1.278"/>
                    <measurement group_id="O3" value="-1.67" spread="0.996"/>
                    <measurement group_id="O4" value="-1.61" spread="1.106"/>
                    <measurement group_id="O5" value="-1.04" spread="1.101"/>
                    <measurement group_id="O6" value="-0.80" spread="1.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="1.302"/>
                    <measurement group_id="O2" value="-2.20" spread="1.354"/>
                    <measurement group_id="O3" value="-1.87" spread="1.024"/>
                    <measurement group_id="O4" value="-2.18" spread="1.286"/>
                    <measurement group_id="O5" value="-1.08" spread="1.127"/>
                    <measurement group_id="O6" value="-0.90" spread="1.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.48" spread="1.338"/>
                    <measurement group_id="O2" value="-2.48" spread="1.474"/>
                    <measurement group_id="O3" value="-2.49" spread="1.199"/>
                    <measurement group_id="O4" value="-2.18" spread="1.441"/>
                    <measurement group_id="O5" value="-2.37" spread="1.202"/>
                    <measurement group_id="O6" value="-2.10" spread="1.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.62" spread="1.354"/>
                    <measurement group_id="O2" value="-2.60" spread="1.642"/>
                    <measurement group_id="O3" value="-2.90" spread="1.279"/>
                    <measurement group_id="O4" value="-3.18" spread="1.484"/>
                    <measurement group_id="O5" value="-2.48" spread="1.181"/>
                    <measurement group_id="O6" value="-2.81" spread="1.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.73" spread="1.509"/>
                    <measurement group_id="O2" value="-2.59" spread="1.644"/>
                    <measurement group_id="O3" value="-3.08" spread="1.539"/>
                    <measurement group_id="O4" value="-2.97" spread="1.550"/>
                    <measurement group_id="O5" value="-2.69" spread="1.043"/>
                    <measurement group_id="O6" value="-2.96" spread="1.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="1.421"/>
                    <measurement group_id="O2" value="-2.85" spread="1.637"/>
                    <measurement group_id="O3" value="-3.25" spread="0.819"/>
                    <measurement group_id="O4" value="-3.23" spread="1.833"/>
                    <measurement group_id="O5" value="-2.73" spread="1.157"/>
                    <measurement group_id="O6" value="-3.23" spread="1.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.03" spread="1.487"/>
                    <measurement group_id="O2" value="-2.98" spread="1.568"/>
                    <measurement group_id="O3" value="-3.36" spread="0.826"/>
                    <measurement group_id="O4" value="-3.14" spread="1.461"/>
                    <measurement group_id="O5" value="-2.84" spread="1.399"/>
                    <measurement group_id="O6" value="-3.07" spread="1.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (All Causalities)</title>
        <description>Treatment-emergent AEs are those with initial onset or that worsen in severity after the first dose of the study medication. All AEs in the table below were treatment-emergent AEs. An SAE is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the participant or may require intervention to prevent one of the other AE outcomes. Severe AEs were defined as AEs that interfered significantly with participant's usual function. Both SAEs and severe AEs were according to the investigator's assessment.</description>
        <time_frame>Baseline (Day 1) through Week 56</time_frame>
        <population>All participants who received at least one dose of the randomized study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (All Causalities)</title>
          <description>Treatment-emergent AEs are those with initial onset or that worsen in severity after the first dose of the study medication. All AEs in the table below were treatment-emergent AEs. An SAE is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the participant or may require intervention to prevent one of the other AE outcomes. Severe AEs were defined as AEs that interfered significantly with participant's usual function. Both SAEs and severe AEs were according to the investigator's assessment.</description>
          <population>All participants who received at least one dose of the randomized study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with severe AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with dose reduction or temporary discontinuation due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (Treatment-related)</title>
        <description>Treatment-emergent AEs are those with initial onset or that worsen in severity after the first dose of the study medication. All AEs in the table below were treatment-emergent AEs. An SAE is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the participant or may require intervention to prevent one of the other AE outcomes. Severe AEs were defined as AEs that interfered significantly with participant's usual function. Both SAEs and severe AEs were according to the investigator's assessment. Treatment-related AEs were also determined by the investigator.</description>
        <time_frame>Baseline (Day 1) through Week 56</time_frame>
        <population>All participants who received at least one dose of the randomized study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (Treatment-related)</title>
          <description>Treatment-emergent AEs are those with initial onset or that worsen in severity after the first dose of the study medication. All AEs in the table below were treatment-emergent AEs. An SAE is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the participant or may require intervention to prevent one of the other AE outcomes. Severe AEs were defined as AEs that interfered significantly with participant's usual function. Both SAEs and severe AEs were according to the investigator's assessment. Treatment-related AEs were also determined by the investigator.</description>
          <population>All participants who received at least one dose of the randomized study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with severe AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with dose reduction or temporary discontinuation due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued From Study Due to Treatment-emergent AEs From Baseline (Day 1) Through Week 56</title>
        <description>An AE is any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of the study medication.</description>
        <time_frame>Baseline (Day 1) through Week 56</time_frame>
        <population>All participants who received at least one dose of the randomized study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
            <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O5">
            <title>Placebo -&gt; PF-06700841 60 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
          </group>
          <group group_id="O6">
            <title>Placebo -&gt; PF-06700841 30 mg QD</title>
            <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued From Study Due to Treatment-emergent AEs From Baseline (Day 1) Through Week 56</title>
          <description>An AE is any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of the study medication.</description>
          <population>All participants who received at least one dose of the randomized study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Otitis media acute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psoriasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time the participants received the study treatment up to 28 days after the last treatment administration (approximately 56 weeks).</time_frame>
      <desc>The analysis of adverse events included all participants who received at least 1 dose of the randomized study treatment. The participants were analyzed according to the study treatment they actually received.</desc>
      <group_list>
        <group group_id="E1">
          <title>PF-06700841 60 mg QD -&gt; PF-06700841 60 mg QD</title>
          <description>PF-06700841 tablet was administered orally at 60 mg once daily (QD) during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="E2">
          <title>PF-06700841 30 mg QD -&gt; PF-06700841 30 mg QD</title>
          <description>PF-06700841 tablet was administered orally at 30 mg QD during both the initial period (from Day 1 to Week 16) and the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="E3">
          <title>PF-06700841 10 mg QD -&gt; PF-06700841 60 mg QD</title>
          <description>PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.</description>
        </group>
        <group group_id="E4">
          <title>PF-06700841 10 mg QD -&gt; PF-06700841 30 mg QD</title>
          <description>PF-06700841 tablet was administered orally at 10 mg QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg QD during the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="E5">
          <title>Placebo -&gt; PF-06700841 60 mg QD</title>
          <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 60 mg during the extension period (Week 17 through Week 52).</description>
        </group>
        <group group_id="E6">
          <title>Placebo -&gt; PF-06700841 30 mg QD</title>
          <description>Placebo matched to PF-06700841 tablet was administered orally QD during the initial period (from Day 1 to Week 16) and PF-06700841 tablet was administered orally at 30 mg during the extension period (Week 17 through Week 52).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v23.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>COVID-19 pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v23.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

